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Combination of Oncolytic Adenoviruses, T-cell Activation, and Blockade of IDO
Metabolic Circuitry for the Treatment of Glioma
Teresa Tuệ-Minh Nguyen, B.S.
Supervisory Professor: Juan Fueyo, M.D., F.A.A.N.

Glioblastoma is the most common malignant primary brain tumor in adults; the current
aggressive treatment results in a 5% five-year survival rate. More effective therapies should be
developed. One promising alternative is oncolytic adenovirus, Delta-24-RGD, which elicits
cancer cell lysis and immunogenic cell death. In fact, Delta-24-RGD produced complete
responses in 20% of recurrent glioblastoma patients through immune mechanisms that activate
anti-tumor cytotoxic properties of T-cells. This cytolytic effect can further be enhanced by adding
immune agonists, namely OX40L, which engages the OX40 receptor to co-stimulate activated T
cells for enhanced proliferation. Hence, we produced the next generation of Delta-24-RGD, called
Delta-24-RGDOX, which expresses OX40L. Our previous publications exhibited enhanced
immune-activating responses and improved survival in glioma-bearing mice treated with Delta24-RGDOX compared to Delta-24-RGD. Nevertheless, maximal survival of glioma-bearing mice
is unattainable, suggesting the presence of sustained immunosuppression within the glioma
microenvironment. For example, indoleamine-2,3-dioxygenase (IDO) is upregulated in
glioblastoma, correlates with poor prognoses, and is a main source of immunosuppression. IDO
is an IFN inducible enzyme that catabolizes tryptophan resulting in diminished proliferation or
apoptosis of surrounding effector T cells. Furthermore, kynurenine (Kyn), a tryptophan
metabolite, induces T-cell differentiation into Tregs. Excess Kyn also activates carcinogenic
transcription factor, aryl hydrocarbon receptor (AhR), which further mediates lymphocyte
dysfunction and immunosuppression. Relating to our studies, the immune stimulating effect of
Delta-24-RGDOX triggers IFN production contributing to a positive IDO-Kyn-AhR feedback
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loop. Additionally, IDO-mediated tryptophan depletion hinders viral replication. Therefore, we
hypothesized that combining Delta-24-RGDOX with IDO inhibitors will improve therapeutic
outcomes and enhance antitumor immune responses of murine glioblastoma. Here, we showed
that Delta-24-RGDOX activated the IDO-Kyn-AhR cascade in glioma cells. Furthermore, we
demonstrated enhanced therapeutic effectiveness of combined IDO inhibitor and Delta-24RGDOX treatment compared to single agents, which was validated in immunocompetent IDOKO mice. The combination treatment efficacy required CD4+ T cell activation and associated with
increased activation of T cells and decreased Tregs and MDSCs. This microenvironment
remodeling correlated with complete tumor elimination. Altogether, Delta-24-RGDOX activates
the IDO-Kyn-AhR cascade, identifying new targets, which when inhibited have the potential to
enhance anti-glioma effects of oncolytic-viruses by reversing tumor immunosuppression.
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Chapter 1: Background and Significance

I. Glioblastoma
Brain tumors or gliomas can be divided into four grades based on its histology. The grade
of gliomas increases proportionally to levels of differentiation or anaplasia and aggressiveness
(1). The highest grade (IV) of glioma is known as glioblastoma and is the most common malignant
primary brain tumor in adults. Glioblastoma is characterized by high mitotic activity with
microvascular proliferation, necrosis, and displays anaplasia. These criteria result in tumors that
that are very aggressive and are considered malignant. Glioblastoma accounts for 15% of all brain
malignancies, and accounts for the majority of primary malignant brain tumor cases at 48% (2).
With the aggressive conventional treatment of maximal surgery, radiation, and adjuvant
chemotherapy, such as temozolomide, the 5-year survival rate remains around 5% and the median
survival is approximately 15 months (3). Recurrence often occurs within 6-12 months because the
tumors are molecularly heterogeneous and the blood-brain barrier is an obstacle for therapeutic
penetration (4). In addition, brain tumors can often employ mechanisms of immunosuppression,
discussed below, which allow for further tumor progression. At present, patients with recurrent
glioblastoma can be treated with bevacizumab which targets vascular endothelial growth factor
(VEGF), and is often used in combination with Lomustine, a DNA alkylating chemotherapy (5).
Other FDA approved treatments for recurrent glioblastoma includes alkylating agent, Gliadel (6),
and Novocure, a device that can be worn as a helmet, and uses electric fields, called Tumor
Treating Fields (7), to treat the solid tumor. Despite the advances made in this field in the past
decades, the survival rates and mortality statistics have remained the same. The need for more
effective therapies to treat both primary and secondary glioblastomas is apparent.
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II. Immunosuppressive Environment of Glioma
Glioblastoma employs various immunosuppressive mechanisms, leading to its
maintenance and progression. Glioblastoma elicits immunosuppression through secretion of
cytokines, employment of immune checkpoints, and modulation of different cell types in the
tumor microenvironment. These mechanisms are often dependent on each other, creating an
immune microenvironment that is favorable for tumor growth.
Glioblastoma cells secrete immunosuppressive cytokines including, transforming growth
factor beta (TGF-β), interleukin (IL)-10, and IL-1, all of which are important in the prevention of
autoimmune diseases (8). Glioblastoma also secretes colony stimulating factor 1 (CSF-1) (9),
which elicits the immunosuppressive M2 phenotype in tumor associated macrophages and thus
leads to a glioma-enhancing environment (10). Adding to the immunosuppression is the secretion
of granulocyte-macrophage-CSF, important for granulocyte and macrophage function, which can
induce the activation of myeloid derived suppressor cells (MDSCs) (11).
Inhibition of immune activating cells is another method employed by glioblastoma for
maintenance of immunosuppression. For example, differentiated dendritic cells are inhibited by
the secretion of VEGF. Dendritic cells are important antigen presenting cells that present antigens
in the context of major histocompatibility complex (MHC), which is required for T-cell activation
(12). Additionally, natural killer cells are inhibited by the secretion of regeneration and tolerance
factor (RTF) (13).
Studies have shown that the expression of immune checkpoint regulators are increased
on glioblastoma cell surfaces and surrounding T cells. Cytotoxic T-Lymphocyte-associated
protein 4 (CTLA-4) is a substantial negative regulator of the immune system and has been seen
to be associated with many cancers, particularly melanoma (14). The activation of CTLA-4
normally functions to regulate over-activity of the host immune system. In the context of cancer,
2

the expression and activation of CTLA-4 will keep the cancer microenvironment suppressed,
allowing for unchecked tumor growth. Activation of T cells requires two basic signals: 1) the
recognition of the antigen presented in the context of MHC by the T-cell receptor and 2) a costimulation signal. This secondary co-stimulation signal includes the interaction of a CD28 family
receptor of the T cell and a ligand of the B7 family of the target cell, such as a tumor cell or
antigen presenting cell. However, the signal conferred by CTLA-4, a member of the CD28
receptor family, and a B7 protein renders an inactive co-stimulation signal, and will not implement
T-cell responses. Thus, CTLA-4 suppresses T-cell responses against tumor cells allowing tumor
growth (15). Programmed death ligand 1 (PD-L1) is also expressed on glioblastoma cells and can
interact with the negative regulating receptor, programmed death 1 (PD-1), which is expressed on
T-cells, to suppress its activity (16).
Regulatory T-cell (Treg) activation also aids in immunosuppression of glioblastoma.
Glioblastoma produces the chemokine C-C ligand 2, which triggers and traffics Tregs to the tumor
site (17). Additionally, Tregs can be activated through the metabolism of tryptophan (Trp) by the
enzyme, indoleamine-2,3-dioxygenase (IDO) (18).
Signal transducer and activator of transcription 3 (STAT3) is ubiquitously expressed in
glioblastoma cells (19). Blockade of STAT3 can upregulate immune activating cytokines,
including IL-6; the presence of hypoxia enhances this pathway, which is a hallmark of many
cancers, including glioblastoma (20). As such, under hypoxic conditions, VEGF signaling
increases, adding to the immunosuppressive and tumorigenic nature of glioblastoma (21).
The mechanisms that glioblastoma cells engage to produce an immunosuppressive
environment are complex. Understanding these mechanisms will allow for new immunotherapeutic approaches.
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III. The IDO Pathway
As mentioned above, IDO is a contributing factor to the immune suppression visible in
glioblastoma patients. IDO was originally discovered in the placenta of pregnant mice, as a
mechanism of immune tolerance against their fetuses during gestation (22). In the context of
cancer, the catabolism of Trp to kynurenine (Kyn) results in various immunosuppressive
pathways allowing the tumor to progress. Of relevance, studies have shown that patients with high
expression of IDO have a poorer prognosis and a diagnosis associated with higher grade brain
tumors, including glioblastoma (23). While three enzymes, Tryptophan-2,3-dioxygenase (TDO),
IDO, and Indoleamine-2,3-dioxygenase 2 (IDO2), regulate the conversion of Trp into downstream
Kyn, TDO is expressed in the liver and neurons and thus its pharmacological targeting may induce
unacceptable toxicity (24), and IDO2, for which expression pattern there are fewer reports, has a
significantly lower enzymatic activity than IDO (25, 26). Hence, most studies targeting the IDO
pathway do not explore IDO2 or TDO.
IDO can be expressed by tumor cells, dendritic cells, and stromal cells. The enzyme can be
activated via engagement of type I and II interferons, oncogenic ligand-receptor signaling
complexes, pathogen associated molecular patterns, PD-1/PD-L1 signaling, or B7 co-stimulation
signals. Immunosuppressive properties of TGF-β have also been implicated in activation of IDO
(27). IDO-mediated tumor-associated immunosuppression is explained by the local depletion of
Trp and, consequently, the excess of Kyn in the tumor microenvironment (23, 27-31).
Downstream Kyn accumulation contributes to the conversion of naive CD4+ T cells into
immunosuppressive FOXP3-expressing regulatory T cells by virtue of the interaction
between Kyn and the aryl hydrocarbon receptor (AhR) (32, 33). In addition, T effector cells that
sense Trp deprivation via the IDO pathway can activate stress kinase signals via GCN2 (general
control nonderepressible 2), resulting in phosphorylation of eIF2 (Eukaryotic Initiation Factor 2),
4

which is a key translation regulator that delays translation and stimulates the integrated stress
response pathway, resulting in cell cycle arrest or apoptosis of these effector T cells (27, 34, 35).
Moreover, this integrated stress response pathway can lead to transcription and expression of
various inflammatory cytokines, such as IL-6 (36), which has been shown to be essential in both
IDO-mediated MDSC formation and tumor growth (37). The deprivation of Trp can also be
sensed by amino acid sensing kinase GLK1, which can control mammalian target of rapamycin
complex 1 (mTORC) responses in T effector cells; in environments of low tryptophan, mTORC1
signaling is inhibited, which in turn, blocks the phosphorylation of ribosomal kinase S6K, which
is involved the process of translation (27, 38). In summary, the activation of IDO employs various
mechanisms of immunosuppression.
Although brain tumors can be targeted by different types of anti-cancer therapies, any antitumor effects can be counteracted by IDO-mediated metabolic and immune suppression
mechanisms to maintain the deep immunosuppressive environment in the core of gliomas. Further
studies have shown how the inhibition of IDO, which may, in itself, be insufficient to reverse the
tumor immunosuppression, but dramatically improves the responses of other common cancer
therapies, most likely due to the conversion by conventional therapies of non-immunogenic
“cold” tumors to immunogenic “hot” tumors, exposing the targets necessary for efficacy of IDO
inhibition (27, 39-41).

IV. The AhR pathway
The deep immunosuppression caused by IDO can be further enhanced by the activation of
downstream receptor, AhR. The production of Kyn by an active IDO enzyme can bind AhR,
resulting in both the expression and activation of IDO, generating a highly immunosuppressive
IDO-Kyn-AhR positive feedback loop. In fact, the IDO-Kyn-AhR circuit is a key player in the
5

immunosuppression of the microenvironment of gliomas and other tumors (28, 29). Reports have
shown that the levels of IDO, Kyn, and AhR are increased in gliomas. This is important because
the activation of IDO and AhR in the tumor microenvironment cooperate to suppress tumorspecific responses, promoting glioma immune evasion and tumor progression (32, 33). For
example, agonists of AhR, including Kyn, can directly aid in the differentiation of naïve CD4+ T
cells to the immunosuppressive regulatory T cell via elicitation of the immunosuppressive
cytokines, IL-10, TGF-β, and VEGFA (29).
When AhR is bound to its activating ligand, such as Kyn, it undergoes a conformational
change that allows it to move into the nucleus to dimerize with its translocator partner, ARNT,
which in turn binds to dioxin responsive elements that lead to the transcription of its target genes
including enzymes from the cytochrome P450 family, like CYP1A1, CYP1A2, and CYP1B1 (42).
These enzymes have been implicated in the metabolism and bioactivation of carcinogens,
including polycyclic aromatic hydrocarbons, which occur naturally in coal, crude oil, and gasoline
(43). Interestingly, increased CYP1B1 mRNA expression is correlated with a poor glioblastoma
prognosis (44).
The activation of AhR also leads to the transcription of certain histone deacetylases including,
HDAC1, which have been implicated in tumorigenesis (45). Furthermore, AhR can induce an
inflammatory signal via IL-6 through dioxin responsive elements. This inflammatory signal can
recruit different inflammatory mediators and growth factors to the tumor cell, allowing it to
undergo growth and proliferation; in addition, these mediators and growth factors can also elicit
CD4+ T cell differentiation into the Treg cell via the same immunosuppressive cytokines (IL-10,
TGF-β, and VEGFA) utilized by Kyn (29). Activation of the IDO-Kyn-AhR cascade also
activates immunosuppressive macrophages; more specifically, AhR has been reported to drive
expression of ectonucleotidase, CD39, in tumor associated macrophages, which can cause the
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dysfunction of cytotoxic CD8+ T cells by producing adenosine which cooperates with CD73,
which has recently been reported to be involved in T-cell co-signaling (46).
The mechanisms of immunosuppression employed by the IDO-Kyn-AhR cascade are
implicated in glioblastoma; this pathway provides several druggable targets that can aid in
improved prognoses of patients with glioblastoma.

V. Targeting the IDO Pathway
IDO has been reported to be overexpressed in various cancers including those of the
cervix, kidney, lung, colon, (47) and brain (23). Moreover, IDO has been reported to protect
mouse tumors from immune rejection (18). Naturally, this has led to pre-clinical studies targeting
IDO as a treatment for cancer. There have been many reports of the use of IDO inhibitors
providing a therapeutic benefit in various mouse models of cancer when combined with cancer
vaccines, immune checkpoint inhibitors, or chemotherapy (18, 48-51). Of relevance, Wainwright
and colleagues showed a durable therapeutic effect of using a triple therapy that blocked IDO,
CTLA-4, and PD-L1 in a murine glioblastoma model (52). These numerous studies led to the
development of several IDO inhibitors to be used in the clinic (53).
Currently, two classes of IDO inhibitors are being used. The first class includes Trp-mimetics,
including Indoximod (1-methyl-D-tryptophan) and 1MT (1-methyl-D, L-tryptophan). Although
the mechanism of Indoximod and 1MT are not fully understood, the negative regulation of
mTORC signaling in T effector cells caused by tryptophan depletion of IDO activation can be
restored with these drugs (54). As such, Indoximod is currently being tested in phase II clinical
trials in combination with cancer vaccines, chemotherapies, or immune checkpoint inhibitors in
various cancer types including leukemia, melanoma, pancreatic, breast, and other solid tumors
(53). A phase I/II study of the use of adenovirus-p53 transduced dendritic cell vaccine combined
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with Indoximod in patients with metastatic solid tumors showed that patients tolerated a
maximum dose of 1600 mg BID with no severe toxicities; determinations of efficacy are
warranted by future trials.
The second class of IDO inhibitors are direct IDO enzyme inhibitors including, Epacadostat,
Navoximod, and BMS-986205, which can shut off any downstream targets of IDO activation
including both the Kyn pathway and the amino acid deprivation stress pathways (27). The most
advanced direct IDO enzyme inhibitor is Epacadostat, which showed encouraging results in
patients with advanced melanoma when treated in combination with PD-1 blocking antibody,
pembrolizumab, in phase I/II trials (55). This prompted the start of a large phase III trial (ECHO301/KN-252) testing this combination in patients with advanced melanoma. The trial was later
closed when initial results from the study showed no therapeutic benefit when comparing the
combination to pembrolizumab alone (56). Intrinsically, this has somewhat dampened the interest
to use IDO inhibitors in the clinic. However, the failure of this drug in the phase III setting may
be attributable to dosing issues or inappropriate patient selection. More investigations that can
elucidate which patients will most likely benefit from IDO blockade is essential. Additionally, the
reported poor prognoses in cancer patients with high IDO expression along with the supporting
pre-clinical evidence demonstrating the anti-cancer effects by targeting IDO with other anticancer drugs warrant further investigation and the continuation of targeting IDO in cancer.
Other novel IDO enzyme inhibitors are also being investigated in pre-clinical models. For
example, Ladomersky and colleagues demonstrated that the use of triple therapy of CNSpenetrating IDO enzyme inhibitor, BGB-5777, combined with a PD-1 monoclonal antibody and
radiotherapy was more therapeutically beneficial then single agents or any dual therapy
combination in a mouse model of glioblastoma (39). The same group was able to validate these

8

results using the clinical grade version of BGB-5777, called BGB-7204 (57), which has been used
in some studies of this dissertation.

VI. Viral Infection and IDO
There have been reports of increased IDO expression and activity during human
immunodeficiency virus (HIV), influenza, hepatitis B virus (HBV), or hepatitis C virus (HCV)
infection (58). This induction of the IDO pathway by these viruses is generated by both type I and
type II interferons. Furthermore, the IDO activation in response to these viral infections results in
immunosuppression.
HIV
There have been several reports linking the IDO pathway to HIV-infected patients. These
patients show increased serum levels of both IFNγ and Kyn (59). Elevated IDO mRNA levels
have also been seen in the peripheral blood mononuclear cells (PBMCs) of patients infected with
HIV (60). One study found that HIV infection of PBMCs in vitro leads to secretion of type I
interferons, IFNα and IFNβ, which was associated with IDO expression and activity (61). In these
same cultures, the use of Trp-mimetic, 1MT, led to the increase of CD4+ and CD8+ T cell
proliferation (60, 61), indicating the immunosuppression aided by IDO. Similarly, IDO enzyme
activity was associated in the antigen presenting cells of HIV-infected patients to reduce anti-viral
T cell responses via regulatory T cells (62).
Influenza
Studies have shown that mouse influenza can induce IDO expression in mouse lung tissue
and nearby lymph nodes (63, 64). Similar to HIV, the mouse influenza virus, X31, induced IFNγ
secretion in the lymph nodes leading to increased IDO production in surrounding non9

hematopoietic cells (64). The treatment of influenza infected mice with 1MT also increased the
number of functionally active CD4+ T cells and virus-specific memory CD8+ T cells (65) and
enhanced Th1 responses via IFNγ secretion by CD4+ and CD8+ T cells (66), indicating the
immune suppression caused by IDO under influenza virus infection.
HBV and HCV
IDO has also been implicated in patients with HBV and HCV chronic infections (67).
These patients also had high systemic Kyn/Trp ratios in their blood compared to healthy controls
(68). In vitro studies demonstrated that PBMC monocytes from HCV patients led to
differentiation of IDO-positive dendritic cells that induced regulatory T cells by LPS or IFNγ
more potently compared to healthy controls (67), again indicating the immunosuppression caused
by IDO.
Adenovirus
Like the viruses mentioned above, IFN activation is triggered by sensing of adenoviral
DNA in the cell. For example, the immune responses by adenoviruses include elicitation of IFNα
via MyD88 signaling of TLR9 (69). Furthermore, IFNβ induction by the adenovirus is required
for viral functions including entry, endosomal escape, and release of the viral DNA into the
cytoplasm (70). While type I IFNs, IFNα and IFNβ, are secreted by adenovirus-infected cells,
IFNγ is produced by T cells and NK cells and plays an important role in cell-mediated immunity
against adenoviruses (71). IFNγ induces an antiviral state so that adenoviral replication is
inhibited. However, E1A gene products can suppress transcription of IFNγ (72). These contrasting
effects of IFNγ by adenoviruses and the T cells or NK cells may represent an example
evolutionary reaction between virus and host. As mentioned above, these IFN responses
associated with adenoviral infection are also directly related to the expression and activation of
IDO. In fact, one report showed that stimulation of dendritic cells with IFNα significantly
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upregulated IDO expression (73). In this dissertation, we show that modified oncolytic
adenoviruses increase the expression and activation of IDO in various human and mouse models
of cancer, including glioblastoma. Furthermore, we demonstrate that these modified oncolytic
adenoviruses also activate the downstream pathway of IDO, AhR.

VII.

Adenovirus Structure and Life Cycle
The structure of the adenovirus is conferred by its genome, which is comprised of about ~

36 kb of linear double stranded DNA. Adenoviruses are classified as non-enveloped and are about
95 nm in size (157 MDa). They have an icosahedral shaped capsid composed of 240 copies of the
hexon protein (II) and 12 penton (III) capsomeres with fiber proteins (IV) attached. Minor capsid
proteins include protein IIIa, VI, VIII, and IX, which stabilize the viral capsid structure and are
involved in endosomal escape and transcriptional activation. Core proteins include the terminal
proteins, V, VII, and mu, all of which interact with the viral DNA to condense it (74).
To start infection, the knob domain of the fiber protein binds to the coxsackie adenovirus
receptor (CAR) or the CD46 receptor to stimulate internalization via clathrin-coated pits. The
fibers shed allowing the endosome to internalize the uncoated virus. Acidification of the
endosome disassembles the viral capsid further, leading to the release of internal proteins into the
endosome. Then, activated viral proteases cleave protein VI, which lyses the endosome to
facilitate viral escape. The partially uncoated virus consequently moves to the nuclear pores via
microtubules with the help of protein VII (75).
After this infection into the nucleus, E1A transcription occurs and stimulates the
transcription of all early viral genes, which affects the transcription profile of the host cell. E1B55K then inhibits p53-induced apoptosis and E1B-19K binds to the BCL-2 family protein
complex BAK-BAX, preventing the formation of mitochondrial pores. After E1A activation,
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transcription of the E3 gene occurs, which encodes for several proteins that inhibit the host innate
and acquired immune response to viral infection. The E4 region has 7 open-reading frames, which
stimulate the production of cellular translational factors, inhibits the cellular DNA double-strand
break response, forms a complex with E1B-55K to inhibit p53, and recruits the cellular
transcription factors to the E2 promoter. The transcription of the E2 region occurs last, and codes
for adenoviral DNA polymerase, ssDNA binding protein, and the preterminal protein, all of which
are required for viral replication (76).
After completion of viral replication, the synthesis of major capsid proteins occurs in the
cytoplasm. Hexon, fiber, and penton assemble into multimeres in the cytoplasm and transport to
the nucleus. With the support of the L1 52/55k protein, the Iva2 protein facilitates DNA packaging
of the virion. DNA packaging is associated with core protein precursors, including protein VI,
VII, VIII and mu. The viral protease cleaves these precursors to produce mature viral particles
(77). The E3-11.6 kDa protein promotes release of these viral particles. These viral particles
interact with the MAD2B gene to promote cell lysis and the consequent infection of surrounding
cells to perpetuate its life cycle (78).

VIII. Delta-24 and Delta-24-RGD
The easy manipulation of the adenovirus makes it a good candidate for oncolytic viral
therapy. Adenoviruses can be easily modified for attenuation, specificity, and cytotoxicity against
tumor cells. In 2000, our group developed tumor selective adenovirus, Delta-24, which relies on
the retinoblastoma (RB) pathway dysregulation, that is present in ~80% of glioblastomas, for viral
replication (79, 80). For adenoviral replication to occur, E1A must bind Rb to release it from E2F,
resulting in cell cycle entry through activation of the E2 promoter (81). Delta-24 contains a 24
base pair deletion of the E1A gene producing a mutant E1A, making it unable to bind Rb. This
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deletion confers specificity to cancer cells since the binding of E1A to Rb will not occur in normal
cells due to a defective E1A protein manifested by the 24bp deletion; thus, replication of the virus
will be inhibited in normal cells. Contrastingly, the Rb pathway is dysregulated in glioblastoma
cells, which allows the cancer cells proliferate uncontrollably; the viral life cycle of Delta-24 can
take advantage of this and will be able to replicate (82).
Infection and internalization depend on viral binding to the coxsackie adenovirus receptor
or the CD46 receptor (83). However, glioma cells do not normally express these receptors. Thus,
to increase the tropism of the adenoviruses to glioblastoma cells, the RGD motif was added at the
carboxyl end of the fiber protein of Delta-24 to produce the next generation virus called Delta24-RGD (84). The RGD motif can bind to RGD-related integrins, such as the αvβ3 and αvβ5
integrins (85), of which are highly expressed on glioblastoma cells (86).
Once infection of cancer cells occur, Delta-24-RGD can cause oncolytic lysis through
autophagy and immunogenic cell death. In vitro and in vivo studies show an increase in autophagy
mediators (87), which is thought to be associated with inhibition of the AKT/TOR pathway (88).
The effect of autophagy made by the adenovirus may be thought of as an innate immune response
because of viral clearance. Moreover, the immune response is increased by proteasome activity,
which generates tumor associated antigens that can be presented in the context of MHC to
cytotoxic CD8+ T-Cells (89).
Our group recently published results from a Phase I clinical trial testing Delta-24-RGD in
patients with recurrent glioblastoma. This trial resulted in 20% of patients living past three years.
Furthermore, the patients who responded portrayed radiographic signs of inflammation, or a
pseudoprogression, followed by a response. Moreover, the clinical trials indicate that part of the
oncolytic virus-mediated anti-glioma effect was due to an anti-tumor immune response as
indicated by the obvious infiltration of immune cells seen in the H&E staining from patient
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biopsies after treatment with Delta-24-RGD. Moreover, these same biopsies of the glioblastoma
in the patients’ post-virus treatment showed infiltration of CD8+ and T-bet T cells, indicating the
elicitation of a Th1 immune response. Importantly, further histological staining indicated that the
virus was cleared within a month of infection. These responses indicate that the anti-viral response
triggered an immune response against the virus and the tumor (90).
One trial (NCT02798406) is currently testing therapeutic efficacy of the combination
therapy of Delta-24-RGD with pembrolizumab, the PD-1 monoclonal antibody, in glioblastoma
patients. The anti-tumor response will be coupled with the inhibition of immunosuppression aided
by PD-1 for a robust immune response against the tumor.

IX. Delta-24-RGDOX
To increase the immune response of Delta-24-RGD, our group developed the next
generation virus, called Delta-24-RGDOX. Delta-24-RGDOX is similar to Delta-24-RGD, in that
it contains the 24 bp deletion in the E1A gene and the addition of the RGD motif, as previously
mentioned. Unlike Delta-24-RGD, Delta-24-RGDOX also contains the OX40-ligand (OX40L)
expression cassette, allowing for expression of this immune agonist on infected cancer cells (91).
OX40L is part of the tumor necrosis factor receptor/tumor necrosis factor family and is expressed
on activated CD4+ and CD8+ T cells, serving as costimulatory signals to promote the proliferation
and clonal expansion of effector and memory T cells (92, 93). Thus, the expression of OX40L on
cancer cells transforms the cancer cells into an ad-hoc antigen presenting cell, thus enhancing the
proliferation of activated T cell clones that can recognize cancer antigen.
Preclinical studies, performed in our lab, indicate that Delta-24-RGDOX is more
therapeutically effective than Delta-24-RGD in a glioblastoma immunocompetent murine model.
Furthermore, when tested in an immune deficient model, the therapeutic efficacy of both Delta14

24-RGD and Delta-24-RGDOX is completely eradicated. Additionally, we observed that Delta24-RGDOX provides a more robust anti-viral and anti-tumor immune response compared to
Delta-24-RGD as indicated by functional co-culture experiments utilizing the brain infiltrating
lymphocytes from these glioblastoma bearing virally treated mice. Moreover, Delta-24-RGDOX
elicited a more immunogenic tumor microenvironment compared to Delta-24-RGD as indicated
by an increase in CD3+, CD4+, and CD8+ T cells (91). Our studies also showed that Delta-24RGDOX increased expression of both MHC1 and MHCII expression on infected cancer cells,
indicating that these tumor cells can act as antigen presenting cells (94). Interestingly, Delta-24RGDOX also increases expression of PD-L1 and PD-1 expression within the microenvironment.
In fact, the combination of Delta-24-RGDOX and PD-L1 antibodies is more effective in treating
murine glioma than Delta-24-RGDOX alone. This indicates that despite the cytotoxic T cell
responses, immune suppression can still be present in Delta-24-RGDOX treated tumors (91). PDL1 engagement has been implicated in IDO activation, which adds to our speculation that Delta24-RGDOX can elicit mechanisms of immunosuppression. As such, Delta-24-RGDOX has
shown to be a good candidate for various combination treatments, including IDO inhibitors.
Glioma is a non-metastatic localized disease, which allows the intra-tumoral injection
within the brain, which will not cause any potential systemic infection. The ease in manipulation
of adenovirus led to the construction of the non-pathogenic Delta-24-RGDOX, which has an
increased tropism to glioma cells and elicits a stronger anti-tumor immune response compared to
its predecessor. The non-lymphocytic nature of the brain increases the chance of viral infectivity,
and thus oncolysis. In addition, Delta-24-RGDOX can elicit an immune response, which can start
off as a response for viral clearance and transform into immunity against the tumor. This
observation, which is also common among other oncolytic viruses (95-98), has led to the paradigm
shift that oncolytic virotherapy should be considered a type of immunotherapy. Stated more
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explicitly, Delta-24-RGDOX can elicit a positive immune response against the tumor by
transforming a non-immunogenic tumor microenvironment (glioblastoma) into an immunogenic
one. This perspective is leading the field to discovering combination treatments with oncolytic
viruses that will synergize with current immunotherapies to increase anti-tumor immunity.

X. Current Landscape of Oncolytic Viruses as Clinical Treatments in Glioma
In addition to the adenovirus (90) family, other families of viruses have been heavily clinically
studied including the herpes simplex virus type I (98-101), reovirus (102-104), Newcastle Disease
virus (105-108), and poliovirus (97). The measles virus (NCT00390299), vaccina virus
(NCT03294486), and the parvovirus (109) have also been tested clinically, however there are
currently no reports assessing their effect on patient survival. The benefits of oncolytic
virotherapy in the treatment of cancers including glioblastoma is that the viruses can elicit cancer
cell death using multiple methods including oncolysis and immunogenic cell death. For example,
upon viral infection, the innate and adaptive immune response can be elicited by danger- and
pathogen-associated molecular patterns (110). The result is an anti-viral immune response that
could also elicit an anti-tumor immune response. In fact, some common effects of treatment of
glioblastoma with different oncolytic viruses includes the induced immunogenicity. Inherently,
this provides a hurdle for oncolytic therapy because the increased immunogenicity is initially
directed towards removing the pathogen from the host. As such, the effectiveness of oncolytic
viruses depends on the balance between the anti-viral immune responses and the virus mediated
anti-tumor immune responses. Despite this obstacle, there have been major strides demonstrating
the therapeutic effect of these oncolytic viruses that are currently being tested in clinical trials.
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Herpes Simplex Virus Type 1 (HSV1)
HSV1 belongs to the Herpesviridae family and is composed of dsDNA that encodes 81
viral genes. For attenuation and specificity three genes are often deleted and include, dlsptk, ү34.5,
and UL39. dlsptk encodes the gene for thymidine kinase, an enzyme that aids in the generation of
thymidine monophosphate, which is important in the process of DNA replication. The deletion of
dlsptk is not sufficient for attenuation, as this single mutation can still cause neuropathogenicity.
Thus, both copies of ү34.5 are often deleted for generation of the oncolytic HSV (111). ү34.5
encodes the gene for ICP34.5. The function of ICP34.5 is two-fold. First, ICP34.5 can recruit
protein phosphatase 1 for the dephosphorylation of phosphorylated eIF2α which leads to the
activation of protein synthesis. Phosphorylated eIF2A, thus, inhibits protein synthesis, which is
an anti-viral defense mechanism that is mediated by host RNA-induced protein kinase R (112).
Second, ICP34.5 forms a complex with proliferating cell nuclear antigen, which aids in DNA
replication and repair (113). The deletion of ICP34.5 thus will decrease the ability of the HSV1
to undergo both DNA replication and translation. This modification also confers specificity
because HSV1 mutants do not depend on ICP34.5 for replication in tumor cells. However, in
normal cells ICP34.5 is crucial for viral replication (114-116). UL39 encodes the gene ICP6,
which translates to the large subunit of ribonucleotide reductase (117, 118). Ribonucleotide
reductase functions to increase the dNTP pools of cells for DNA replication. However, in cancer
cells, the dNTP pools are quite abundant and thus do not depend on ribonucleotide reductase for
replication (119). Thus, this mutation confers specificity because the lack of a functional
ribonucleotide reductase in normal cells will not allow for the replication of the viral DNA.
Currently, there are four different oncolytic HSVs being tested in clinical trials. These
include HSV1716, G207, rQNestin34.5, G47Δ, and M032. HSV1716 contains the deletion of
both alleles of ү34.5. HSV1716 has been tested in four clinical trials. All these clinical trials show
17

the safety of this attenuated virus. Of the available data, HSV1716 show survival of patients for
14-24 months after treatment in 11 of 21 GB patients (99, 101, 120). G207 contains the deletion
of both alleles of ү34.5 and a lacZ gene insertion in the ICP6 gene. G207 has been tested in three
Phase I clinical trials in a total of 36 patients of malignant glioma (98, 100, 121). The trials show
the safety of the attenuated virus. Although tumor decreases were seen in 11 of 36 patients, the
median survival was not ameliorated compared to results from use of conventional therapy. The
treatment of glioma using G207 before and after resection yielded a median survival of 6.6 months
(100). The use of G207 preceding irradiation yielded a median survival of 7.5 months (98).
Despite these data, some patients can benefit greatly from G207, and MRI images suggest antitumor activity (121). This anti-tumor effect may be attributed to the anti-tumor immune response.
GB patients that receive G207, resections show increases in CD3+, CD8+, and HAM56+ immune
cells suggesting both an innate and adaptive immune response against the tumor (100). In a
different patient cohort, G207 showed a 20% response rate in pediatric patients with high-grade
glioma, with a median overall survival of 12.2 months, which is higher than the medial overall
survival of the primary disease (122). Two other oHSVs are also in Phase I clinical trials and
include rQNestin34.5, G47Δ, and M032, but the data from these open trials are unpublished.
rQNestin34.5 was developed to increase replication in GB cells through the reinsertion of one
copy of ү34.5 into the UL39-deleted, ү34.5-delted viral genome, which is controlled by the nestin
promotor (123). G47Δ is an extension of G207 and contains the deletion of the α47 gene, which
increases MHC class I expression to aid in mediation of antigen presenting for T lymphocytes
(124). M032 lacks both copy of γ34.5 and expresses IL-12 to increase the antigenic stimulation
response of the tumor microenvironment (125). G47Δ and M032 are relatively new to the clinic,
but the pre-clinical data show that they can modulate the immune system for a greater cytotoxic
immune response against the tumor (124, 125).
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Reovirus
Of the Reoviridae family, reovirus is a non-enveloped RNA virus that can cause
asymptomatic or mild intestinal infections in human beings. The reovirus is considered to be a
natural oncolytic virus because it specifically replicates in cells that employ RAS activation,
which include glioma cells (126). Pre-clinical studies revealed that reovirus can elicit complete
regression in subcutaneous and intracranial glioma mouse models (127), and can elicit increased
T-cell infiltration and Type I IFN responses (104). The clinical translation of reovirus into the
clinic revealed that this virus produces no adverse effects (102, 103), and generated increased
tumor leukocyte infiltration along with upregulated expression of IFN, caspase 3, and PD-L1
within the brain tumor of the treated patients (104). There are currently no reports assessing the
survival of glioblastoma patients being treated with reovirus.
Newcastle Disease Virus (NDV)
Of the Paramyxoviridae family, NDV encapsulates negative sense, single-stranded RNA.
Because NDV infects mainly avian species, there is minimal pathogenicity in human beings (128).
The replication of NDV depends on deficiencies of the type I IFN response (107, 129).
Furthermore, published reports described the requirement of GTPase Rac1 for the replication of
NDV; GTPase Rac1 maintains glioblastoma stem properties (130, 131). Pre-clinical studies
revealed that NDV provides an enhanced anti-cancer effect in type I IFN-deficient glioblastoma
cells (132). Still, the use of glioblastoma mouse models showed the apoptotic and therapeutic
effect of NDV either alone or in combination with temozolomide (133-136). NDV has been tested
in several studies ranging from phase 0 to phase II. The use of the mesogenic strain of NDV called
MTH-68/H for the treatment in human high-grade glioma resulted in survival rates lasting 5-9
years (105). Similarly, there was an increase in overall survival in patients with recurrent glioma
after treatment with NDV infected dendritic cells (107). A different phase I/II study testing a
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lentogenic NVD strain called OV001/HUJ revealed a 7% complete response rate in patients with
recurrent glioblastoma (106).
Poliovirus
Of the Picornaviradae family, polioviruses encapsulate single strand RNA. Unattenuated
polioviruses generate neurotoxicity. To make polioviruses clinically relevant, Gromeier and
colleagues developed an unattenuated polio–rhinovirus chimera, called PVSRIPO, which
replaced the internal ribosome entry site of the Sabin strain of the poliovirus vaccine with the nonvirulent human rhinovirus type 2 (137). Pre-clinical studies of PVSRIPO proved its ability to
infect and kill glioma cells both in vitro, which was associated with enhanced survival of glioma
bearing mice in vivo (138-140). Results from an interventional study testing PVSRIPO in 61
patients with recurrent glioblastoma showed 21% of patients surviving after 36 months (97). A
phase II study (NCT02986178) and a phase Ib study (NCT03043391) are currently ongoing.

XI. Hypothesis and Aims
Glioblastoma is the most common malignant primary brain tumor in adults. Conventional
treatment of glioblastoma includes chemotherapy, radiotherapy, and surgery. However, upon
diagnosis, and with the aggressive conventional therapies, the median survival is about 15 to 17
months (2). Alternative forms of glioma therapy are crucial. Oncolytic viruses (OV) provide a
promising alternative to current treatment because it induces cell death by several cytotoxic and
immune mechanisms that stem from direct lysis (141, 142). In addition, because apoptosis is not
the OV’s mode of killing, apoptosis-resistant glioma cells are not the basis of recurrence. Delta24-RGD is an OV that is highly replicative and tumor specific (89, 143). Delta-24-RGD has been
translated to the clinic and was tested in Phase I and II clinical trials. Recently published data
from a Phase I Study show that treatment of recurrent glioblastoma with Delta-24-RGD led to
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complete tumor regression in 20% of patients (90). Moreover, the clinical trials indicate that part
of the OV-mediated anti-glioma effect was due to an anti-tumor immune response, as indicated
by the presence of pseudoprogression and an infiltration of CD8+ T cells. In this regard, preclinical studies of Delta-24-RGD in glioblastoma have shown that in addition to the production
of pathogen associated molecular patterns, the adenovirus infection induces autophagy, a
mechanism underlying antigen presentation and immunogenic cell death with production of
damage associated molecular patterns (89, 143). Thus, the Delta-24-RGD infection of the cancer
cells elicits an anti-viral immune response that eventually becomes an anti-tumor immune
response in a small percentage of patients. Further enhancement of the immune component of
oncolytic viral therapy should increase the percentage of glioblastoma patients sensitive to Delta24-RGD. One approach to increase the cytotoxic immune response consists of the modulation of
T-cell immune checkpoints (41). Based on this tenet, our group recently generated an immuneagonist armed version of Delta-24-RGD, named Delta-24-RGDOX, which express the immune
co-stimulatory molecule, OX40L, a member of the tumor necrosis factor superfamily, and is a
positive regulator or agonist of the immune synapsis and enhances the activation and proliferation
of cytotoxic T-cells through co-stimulation (92, 93, 144). Our recently published data show that
Delta-24-RGDOX has a superior anti-tumor effect compared to Delta-24-RGD in an orthotopic
glioblastoma immunocompetent mouse model (91). We hypothesize that Delta-24-RGDOX will
directly enhance the activity of cytotoxic T-cells against glioblastoma. We are also taking into
consideration that a positive activation of lymphocytes can be halted by the immune suppressive
tumor microenvironment. For example, T-cell anergy can occur when the T-cell receptor engages
the MHC-antigen complex without a co-stimulatory signal, to result in a non-active T cell and
subsequent tolerance of the tumor, as seen with engagement of CTLA-4 or PD-1 (145).
Particularly, indoleamine-2,3-dioxgenase or IDO, has been reported to cause T-cell anergy (146).
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Of importance, IDO is upregulated in high-grade glioma and correlates with a poor prognosis (18,
23). In the setting of cancer immunology, the catabolism of tryptophan by IDO is sensed by the
surrounding T cells, eliciting stress responses to prompt cell cycle arrest (146, 147) and decreases
in proliferation (148). Furthermore, the metabolites of tryptophan, including kynurenine, can
induce apoptosis of effector T-cells and its differentiation into immunosuppressive regulatory T
cells through activation of the aryl hydrocarbon receptor (AhR) (32, 33, 149-151). Activation of
AhR also stimulates dioxin responsive elements that aid in transcription of carcinogenic
mediators. Furthermore, AhR activates immunosuppressive macrophages, and other populations
of cells causing immunosuppression (46). Of relevance to our study, IDO expression increases
dramatically after virus infection and is inducible by IFNү (63, 152), which is a direct effect of
adenoviral infection. Moreover, the use of IDO inhibitors has been seen to reverse immune
resistance

in

IDO-expressing

tumors

(18).

Collectively,

these

data

suggest

the

immunosuppression by IDO and the activity of a continual feedback loop of IDO during a viral
infection, providing the rationale to target IDO in combination with the treatment of the Delta24-RGDOX. In summary, a functional IDO can cause immunosuppression within the tumor
microenvironment and thus decrease the immune effects of oncolytic viruses. Based on these
observations, the central hypothesis of this study is that therapy of Delta-24-RGDOX combined
with an IDO inhibitor will stimulate a cytotoxic immune response and inhibit the suppressive
immune response against the tumor cells providing a potential effective novel treatment for
glioblastoma. Figure 1 shows the current working model of our proposed hypothesis.
To test the central hypothesis and achieve the objectives of the project, we proposed the following
two specific aims:
Aim 1: Compare the therapeutic efficacy of using Delta-24-RGDOX with and without
IDO inhibitors in mouse models of glioblastoma.
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Aim 2: Analyze the ability and effectiveness of Delta-24-RGDOX in combination with IDO
inhibitors to reshape the murine glioblastoma microenvironment.
Accomplishing the aims of this project will provide valuable information about the effects of
manipulating several axes of the immune system to achieve an anti-tumor immune response and
will elucidate the role of immunomodulators and IDO in T-cell anergy during active virotherapy.
These results should provide the basis for the future translation of the proposed strategy to the
clinical setting.
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Figure 1: The current working model of our proposed hypothesis.
Infection of the glioblastoma cell by Delta-24-RGDOX can increase the expression and activation
of IDO via IFN responses. The subsequent activation of IDO catabolizes tryptophan (L-Trp) into
kynurenine (Kyn). Kyn acts as an activating ligand for the carcinogenic transcription factor, aryl
hydrocarbon receptor (AhR). Activation of AhR by Kyn will translocate it to the nucleus and
promote stimulation of dioxin responsive elements (DRE), which aid in transcription of target
genes of the glioblastoma cell that will result in carcinogenesis and immunosuppression.
Activation of the IDO-Kyn-AhR pathway in immune cells can decrease proliferation and
function, limiting the immune response against cancer cells. Overall, the effect of infection of
glioblastoma by Delta-24-RGDOX will produce an immunosuppressive microenvironment via
the IDO-Kyn-AhR pathway, which when targeted can combat the tumor cells and lead to tumor
elimination.
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Chapter 2: Materials and Methods
Cell Lines
Mouse glioma cell lines, GL261, GL261-5 (GL261 isolated clone with slower in vivo
growth kinetics than parental cells) (91), or GL261-IDO-OE (the GL261 cell line with constitutive
IDO overexpression, kindly provided by Dr. Derek Wainwright of Northwestern University,
Feinberg School of Medicine) were cultured in Dulbecco’s modified Eagle’s medium with
nutrient mixture F12 (DMEM/F12). Mouse GSC-005 cells (kindly provided by Dr. Inder M
Verma of the The Salk Institute for Biological Studies) were maintained in DMEM/F12
supplemented with N2 (1x, Invitrogen), fibroblast growth factor-2 (20 ng/mL, PeproTech),
epidermal growth factor (20 ng/mL, Promega), and heparin (50 μg/mL, Sigma). Mouse melanoma
cell line B16-F10 and mouse breast cancer cell line 4T1.2 cells expressing the luciferase gene
(kindly provided by Dr. Chandra Bartholomeusz of the University of Texas MD Anderson Cancer
Center) were both maintained in RPMI 1640 medium. Human HeLa and HEK293 cells were
maintained in DMEM, and human A549 cells were maintained in DMEM/F12. Human neuronal
or glioma stem cell (NSC or GSC) lines NSC11, GSC20, GSC7-2, GSC13, and GSC8-11 were
cultured in DMEM/F12 with B27 (1x, Invitrogen), antibiotic-antimitotic (1x, ThermoFisher
Scientific), basic fibroblast growth factor (20 ng/mL, Sigma), and epidermal growth factor (20
ng/mL, Sigma). Cultures, except for cultures of GSCs, were supplemented with 10% fetal bovine
serum (HyClone Laboratories) and antibiotics (100 μg/mL penicillin; 100 μg/mL streptomycin)
(Corning). All cells were kept at 37˚C in a humidified atmosphere containing 5% CO2.
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Oncolytic Adenoviruses
Two previously constructed oncolytic adenoviruses, Delta-24-RGD (80) and Delta-24RGDOX (91), were propagated in human lung carcinoma A549 cells. Virions were collected and
purified using the Adenopure kit (Puresyn, Inc, Malvern, PA) following the manufacturer’s
instructions. Viral titers and replication were determined by measuring plaque-forming units per
mL (pfu/mL), by conventional methods. Briefly, HEK293 (2.5 x 105) cells were incubated in 24well plates with serial dilutions of the viral stock. Forty-eight hours later, cultures were fixed with
100% ice-cold methanol for 10 min at -20°C. Cells were stained for hexon expression using an
anti-adenovirus polyclonal antibody (1 h, 37˚C) (anti-adenovirus, Millipore Sigma, AB1056),
followed by secondary staining with a biotinylated anti-goat IgG (1 h, 37˚C) (Biotinylated antigoat IgG (H+L), Vector Biolabs, BA-5000). The Vector Vectastain ABC kit (PK-4000) and
ImmPACT DAB peroxidase substrate kit (SK-4105) was utilized for visualization of positive
cells. Hexon-stained areas were counted under a light microscope (20× objective) in 10 individual
fields per well. In wells with viral dilutions showing 5-50 positive cells/field, the viral titer was
calculated using the following formula: pfu/mL = [(mean number of positive cells/field) *
(fields/well)] / [volume virus (mL) * dilution factor].

IDO Inhibitors
For mice treated with IDO inhibitors, the following reagents were administered:
Indoximod or 1-methyl-DL-tryptophan (1MT) (both purchased from Sigma-Aldrich) suspended
in PBS containing glass balls (3mm, Thomas Scientific, #3000) and rotated overnight to help resuspend the drug to form a uniform and smooth solution. We also used a clinical grade direct
enzyme inhibitor called BGB-7204 (kindly provided by Dr. Derek Wainwright of Northwestern
University, Feinberg School of Medicine), which was suspended in Ora-Plus (Oral Suspending
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Vehicle from Perrigo), and whose pharmacokinetic/pharmacodynamics properties were
previously described (57). For in vitro use of these inhibitors, DMSO was used as the diluent, and
stored at -80°C in between uses.

In Vivo Studies
For glioma tumor implantations, 5 × 104 GL261-5 or GSC-005 cells/mouse or 1 × 103
B16-F10 cells/mouse were implanted into the caudate nucleus of 7- to 10-week-old male or
female C57BL/6 mice by using a guide-screw system as previously described (84), and then mice
were randomly assigned to experimental groups. Treatment began 7 days after tumor cell
implantation. Delta-24-RGDOX adenoviruses (5 × 107, 2.5 × 107, 1.25 × 107, or 1 × 108 pfu/dose,
depending on the study) were injected intratumorally on days 7, 9, and 11. For 4T1.2 breast cancer
tumor implantation, 1 × 104 cells were injected into the right mammary pad of 7-to 10-week-old
female BALB/c mice; intratumoral Delta-24-RGDOX injections were administered on days 10,
14, 16, 18, and 21. Indoximod (275 mg/kg), 1MT (400 mg/kg), or BGB-7204 (100mg/kg) was
administered twice daily, by oral gavage, 5 days/week, for 28 days. Mice surviving 120 days were
re-challenged with a new intracranial tumor injection using GL261-5 cells (5 × 104 cells/mouse)
on the contralateral side of the initial tumor injection. For the CD4 depletion experiment, antiCD4 depletion antibodies (200 µg per dose, clone GK1.5, InVivoMAb, BioXcell) and rat IgG2b
isotype control (anti-keyhole limpet hemocyanin, 200 µg per dose, InVivoMAb, BioXcell) were
administered intraperitoneally in mice starting on day 4 post tumor implantation and continued
every fourth day until day 36. C57BL/6 IDO-KO (B6.129-Ido1tm1Alm/J ) mice were purchased by
The Jackson Laboratory, and bred in our mouse housing facility. All experimental procedures
involving mice were performed in accordance with protocols approved by the Institutional Animal
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Care and Use Committee of MD Anderson Cancer Center, National Institutes of Health, and
United States Department of Agriculture guidelines.

RNA-sequencing and data analysis
Total RNA was extracted from flash frozen tumor using the RNeasy Plus Mini Kit
(Qiagen). Sequencing was performed by Novogene. Quality control of RNA was performed to
measure quantification using Nanodrop, test RNA degradation or potential contamination using
agarose gel electrophoresis, and check for RNA integrity using Agilent 2100 Bioanalyzer System.
Library construction was developed from mRNA eukaryotic organisms, which was enriched using
oligo(dT) beads. This eukaryotic mRNA is then fragmented randomly in fragmentation buffer,
followed by cDNA synthesis using random hexamers and reverse transcriptase. After first-strand
synthesis, a custom second-strand synthesis buffer (Illumina) is added with dNTPs, RNase H, and
Escherichia coli polymerase I to generate the second strand by nick-translation. The final cDNA
library is ready after a round of purification, terminal repair, A-tailing, ligation of sequencing
adapters, size selection, and PCR enrichment. Sequencing was performed using HiSeq machines
(Illumina). Key steps of RNA-seq data analysis include evaluation of quality of reads by fastqc
(fastqc/0.11.8) followed by removal sequencing adapters and unpaired reads by trimmomatic
(trimmomatic/0.33). (153) These trimmed FASTQ files were used to map reads to mouse genome
/ENSEMBL.mus_musculus.release-75 by STAR aligner (star/2.6.0b) (154). Feature Counts
extracted from resulting .bam files by subread (subread/1.6.3) (155). Estimates of unwanted
variations in raw read counts across samples were determined by ‘remove unwanted variation’ on
Galaxy platform (RUVs: which estimates the factors of unwanted variation using replicate
samples) (156). RUV uses the empirical Bayes approach to estimate a moderated t-statistic. These
estimates were used as batch factors in DESeq2 analyses to determine differentially expressed
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genes in the group comparisons (157). For preparation of heatmaps, log2 normalized values for
genes with significant adjusted p-value (<0.05) from DESeq2 analyses was utilized; both rows
and columns were hierarchically clustered using one minus pearson correlation with average
linkage. For gene ontology (GO) enrichment analysis, log2(FC) values for genes with significant
adjusted p-value (<0.05) from DESeq2 PBS vs. RGDOX analyses; enrichment analyses were
performed on http://www.pantherdb.org/, with false discovery rate (FDR) correction. Cutoffs for
ingenuity pathway analyses (IPA), were p-value ≤0.05 and log2(FC) = ±1; activation z-score are
plotted on graphs. Activation z-score of ±2 was considered significant. Expression levels of genes
with significant fold change and p-values in PBS vs RGDOX analysis were overlayed onto IDO1
network (curated from IPA’s knowledge base). For the prediction of immune cell compositions
as inferred from RNA-seq data, we input transcripts per million (TPM) for each sample to seqImmuCC platform (158), the predicted percentages of various immune cell populations in each
sample were plotted in excel. The gene set enrichment analyses were performed by utilizing
GSEA_4.0.3 software, where whole genome expression profiles of PBS and Delta-24-RGDOX
treated tumors were used as input. The Treg gene set was curated from IPA’s knowledge base and
the MSDC gene set was based on previous publication (159).

Viral Replication Assay
To determine the replication ability of Delta-24-RGDOX in the cell lines used in this study
we performed the viral replication assay. For adherent cells, we seeded 1.5 x 105 cells/well in a
12 well plate, then counted the cells after letting them attach overnight to calculate the appropriate
amount of Delta-24-RGDOX needed to achieve specified multiplicities of infection (MOI). Delta24-RGDOX was diluted in PBS to achieve the certain MOI and added dropwise to the attached
cells in 200 µL of serum free media for 20 min at 37˚C and shaken to disperse the virus every 5
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min, after which was replaced with 1 mL of complete medium for 48 h. For non-adherent cells,
infection occurred in 200 µL of serum free media for 20 min at 37˚C and shaken to disperse the
virus every 5 min, after which, 800 µL of complete medium was added for 48 h. After the 48 h
incubation period, cells and supernatant were collected, flash frozen and thawed 3x, then
centrifuged at 500g for 5 min. The supernatant was used for viral titration in 293 cells, as
explained in the “Oncolytic Adenoviruses” section in methods.

Viral-Induced Cytopathic Ability of Virus Assay
To determine the viral-induced cytopathic ability Delta-24-RGDOX in the cell lines used
in this study, we seeded 1 x 104 cells/well in a 96 well plate at 75 µL. An additional 75 µL was
added to the cells containing the appropriate treatment. Viral-induced cytopathic ability was
measured every 24 h for up to 168 h, via levels of ATP using the ViralToxGlo Assay (Promega)
according to the manufacturer’s protocol.

AhR Activity Assay
To assess the activity of AhR by Delta-24-RGDOX, cells were uninfected or infected with
50 MOI of Delta-24-RGDOX and incubated for 48 h; cell supernatants were used in a
commercially available Human Aryl Hydrocarbon Receptor (AhR) assay kit (INDIGO
Biosciences), which uses AhR Reporter Cells that give off a luminescent signal when AhR is
activated. The protocol was performed according to the manufacturer instructions.

AhR Immunofluorescence
HeLa cells were seeded in a 96-well clear bottom black sides tissue culture plate (Corning)
at a density of 1 x 104 cells per well. Cells were uninfected (mock), treated with 150µM of Kyn,
30

or infected with 25 MOI of Delta-24-RGDOX in complete media for 48 h. Following treatment,
immunofluorescence staining was performed by following the procedures provided by the
manufacturer of the primary antibody. Briefly, cells were washed with PBS and fixed with 4%
formaldehyde in PBS for 10 minutes at RT. After washing the wells three times with wash buffer
(2mg/ml BSA in PBS), cells were permeabilized with 0.2% triton X-100 in wash buffer for 30
minutes at RT in moist chamber. After permeabilization, cells were washed three times with wash
buffer and overlaid with primary antibody against AhR (SantaCruz, SC-74572) using a 1:100
dilution in 2mg/ml BSA in PBS overnight. After primary antibody incubation, cells were washed
three times with wash buffer and incubated with FITC conjugated secondary antibody (Invitrogen,
Alexa Fluor 488 Goat anti Mouse, A11001) at 1:100 dilution for 1 h at RT. Cells were washed
four times with wash buffer and then stained for DAPI (1µg/ml). Cells were then overlaid with
mounting medium and imaged using a Zeiss Axiovert200. Cellular and nuclear quantification of
AhR intensities was performed using ImageJ software.

Quantitative Real-Time Polymerase Chain Reaction
To isolate mRNA from cultured cells, Trizol Reagent was used according to the
established routine protocol; to isolate mRNA from freshly dissected tissue samples, the RNeasy
Plus Mini Kit (Qiagen) was used. One microgram of total RNA was reverse-transcribed into
mRNA using the High Capacity RNA-to-cDNA Kit (Applied Biosystems). Quantitative real-time
polymerase chain reaction (qRT-PCR) was performed on the 7500 Fast Real-Time PCR System
(Applied Biosystems) using SYBR Green PCR Master Mix (Applied Biosystems). Primers were
purchased from Sigma Aldrich (human IDO, R: TGGAGGAACTGAGCAGCAT, F:
TTCAGTGCTTTGACGTCCTG; mouse IDO, R: TTGCGGGGCAGCACCTTTCG, F:
CCCACACTGAGCACGGACGG). The RT-PCRs were conducted in a 96 well plate and
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subjected to a 10 min 95˚C holding stage followed by 40 cycles of 30 sec at 95˚C, 30 sec at 60˚C
and, 45 sec of 72˚C, followed by an infinite hold at 4˚C. Relative gene expression was calculated
using the 2−ΔΔCt method by normalizing the threshold cycle (Ct) values of the gene of interest to
the Ct values of the internal housekeeping gene.

Western Blots
To detect protein expression, cell lysates were prepared using RIPA lysis buffer (20mM
HEPES pH 7.0, 200mM NaCl, 1mM EDTA, 1mM EGTA, 1% Triton X-100, 5mM sodium
pyrophosphate, 80mM β-glycerophosphate, 50mM NaF, 0.1% SDS) plus freshly added protease
inhibitor cocktail (1x, Sigma-Aldrich), proteasome inhibitor (MG-132, 1µM, Calbiochem), and
phosphatase inhibitor cocktail 3 (2.5mg/ml, Sigma-Aldrich). Cell lysates were flash frozen in
liquid nitrogen 3x, and centrifuged for 10 min at 4C, 13,000 rpm. Supernatants were collected,
and the concentration of protein was measured using the Bradford Protein reagent (Bio-Rad,
Hercules, CA). DTT (50 mM) and NuPAGE LDS sample buffer (ThermoFisher) were added to
10-15 g of total protein. After heated at 95C for 5 min, samples were run on 4-20% Novex TrisGlycine gels (Invitrogen), and then transferred to a PVDF membrane (ThermoFisher) and probed
with primary antibodies overnight at 4°C (Table 1 shows antibodies and working dilutions),
followed by 1hr secondary antibody staining at RT the next day. Protein bands were visualized
using Western Lightning Plus-ECL, Enhanced Chemiluminescence Substrate (Perkin Elmer).
Images were acquired using the ChemiDoc System (Bio-Rad).

Liquid Chromatography- Mass Spectrometry (LC-MS)
To detect IDO activity, we measured kynurenine and tryptophan levels of differently
treated flash frozen brain tumors. Liquid Extraction was used for the extraction of polar
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metabolites from the frozen brain tissue. Briefly, 400 µL of 80% methanol was added to the frozen
tissue. Zirconia/silica beads (1mm diameter) were added to the tube. The tissue was broken down
using a bead beater by pulsing the tissue for 45 seconds. The resulting solution was kept on ice
for 30 min to precipitate out the proteins. 400 µL of chloroform was added and the tube pulsed in
the bead beater for additional 45 sec and kept in ice for 15 min. 200 µL of water was added to
induce phase separation. The tube was centrifuged and the upper aqueous phase containing the
amino acids/amines was carefully transferred into another tube. 250 µL of the 500 µL aqueous
phase was dried under using a vacuum. The dried tube containing the metabolites was resuspended
in 40µL of buffer used for the derivatization of the amino acids/amines. 10 µL of this was taken
for further derivatization and analysis by LC-MS. Standard calibration curves of known
concentration of amino acids including tryptophan and kynurenine were made. Before analysis
by LC-MS, 5 µM of stable isotope labeled amino acids including tryptophan and kynurenine in
10 µL are added to each sample. The concentration in the analysis sample is then calculated using
linear regression on the standard concentrations by plotting area ratio (ratio of the peak area of
analyte to peak area of the internal standard) and the known concentrations, followed by
normalization to tumor mass.

Preparation of Single Cell Suspensions from Murine Brains and Spleens
Mouse hemispheres bearing tumors and spleens were collected. Initial suspensions were
obtained by cutting the tissue or grinding the organs and filtered through 100-μm cell strainers
(Fisher Scientific), then placing the cell suspension in RPMI 1640 medium (10 mL/sample). All
tissues were pelleted by centrifugation (500 × g for 7 min at RT). The spleen-derived pellet was
re-suspended in Red Blood Cell Lysing Buffer Hybri-Max (Sigma-Aldrich) to lyse the red blood
cells, according to the manufacturer’s instructions. Then, the cell suspension containing the Red
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Blood Cell Lysing Buffer was brought up to 20 mL/sample with RPMI 1640 medium to stop the
lysis reaction, and the cells were washed 1x in PBS. For the brain-derived pellet, 1 wash in HBSS
(Corning) was performed, followed by incubation of cells in 8 pg/mL of Liberase TM (Millipore
Sigma) and another wash in HBSS, then resuspended in 40% percoll (1.130 g/mL; GE
Healthcare), which was overlaid on top of 80% percoll at a 1:1 ratio. The cells were centrifuged
for 20 min at 500 × g at RT with an acceleration of 1 and a deceleration of zero, and the
lymphocyte gradient interphase was collected and washed once with PBS. The cells from the
brains and spleens were pelleted by centrifugation at 500 × g for 7 min at RT and finally resuspended in FACS buffer (1x PBS containing 10 mM HEPES, 2 mM EDTA, and 1% fetal bovine
serum).

Flow Cytometry Analysis
To analyze cell surface protein expression, using a 96-round bottom plate, single cell
suspensions from murine brains and spleens were first blocked in Anti-Mouse CD16/CD32 Fc
Block (eBioscience; 14-0161-85) diluted with FACS buffer and then washed once with 250 µL
of cold PBS. The cells were then incubated in 100 µL of diluted viability dye (please see Table 1
for details) at 4°C in the dark for 30 min and then washed once with 250 µL of cold PBS. Then,
the cells were incubated in 100 μL of primary antibody solution diluted in FACS buffer. After
incubation at 4°C in the dark for 30 min, the cells were washed once with 250 µL of cold PBS.
For

analysis

of

intracellular

proteins,

cells

were

stained

with

the

eBioscience

FOXP3/Transcription Factor Staining Buffer Set (Invitrogen) following the manufacturer’s
instructions. The cells were finally re-suspended in 0.3 mL of FACS buffer containing 123count
eBeads Counting Beads (Invtirogen), to acquire an accurate output for absolute cell count. The
stained cells were then analyzed by using the BD Celesta Flow Cytometer (BD Biosciences).
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FlowJo software, version 10 (FlowJo, LLC), was used for the analysis. (Table 1 shows the
antibodies and working conditions used.) To control for the technique and to arrange population
gates accurately, we generated fluorescence minus one (FMO) samples for each antibody using
pooled spleen cells from the differently treated brain tumor bearing mice.

Analysis of Stimulation of Splenocytes in Co-Cultures with Target Cells
Co-culture set up
Indicated target cells were seeded and treated with specified treatment. Four hours later,
100 units/mL of mouse interferon gamma (IFNγ) (ProSpec Protein Specialists) were added to the
cultures. Forty-eight hours after viral infection, the cells were detached with 2 mM EDTA in PBS,
fixed with 1% paraformaldehyde, and cleaned with lysine (0.1 M) wash solution. A total of 2 ×
104 fixed cells were seeded in 96-well round-bottom dishes. To activate immune cells, pre-fixed
target cells were co-cultured with splenocytes (5 × 105/well) in RPMI 1640 medium containing
100 μg/mL penicillin (Corning), 100 μg/mL streptomycin (Corning), and 55 µM betamercaptoethanol (Gibco) for 48 h.

Please refer to section “Preparation of Single Cell

Suspensions from Murine Brains and Spleens” for description of how splenocytes were
processed into single cells.
IFNγ or IL-2 ELISA
For analysis of stimulation of splenocytes in co-cultures with target cells, the
concentration of IFN or interleukin-2 (IL-2) in the supernatant was assessed with a standard
ELISA per the manufacturer’s instructions (IFNγ or IL-2 DuoSet ELISA, R&D Systems).
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Histopathological staining
Mouse brains bearing tumors were fixed in 10% buffered formalin for 24 h, transferred to
70% ethanol, and then embedded in paraffin for slide sectioning. Paraffin-embedded sections of
the mouse brain tumors were deparaffinized at 60°C for 1 h and rehydrated with xylene and
ethanol following conventional procedures. For hematoxylin and eosin staining, brain tumor
sections were stained with Harris hematoxylin (Fisher Scientific) and Eosin-Y solution (Fisher
Scientific)

and

mounted

with

Cytoseal

60

(Thermo

Scientific).

For

the

CD3

immunohistochemistry, antigens were retrieved from the brain tumor sections by exposing the
slides to 10 mM citric acid (pH 6.0) inside a steamer for 30 min. Slides were then incubated in
3% hydrogen peroxide in 100% methanol for 10 min at RT to quench endogenous peroxidases.
The sections were then subjected to blocking with 5% goat serum in PBS (1 h at RT), followed
by incubation in primary rabbit monoclonal anti-CD3 antibody overnight (1:80, Abcam, ab16669)
and incubation with a biotinylated anti-rabbit IgG secondary antibody diluted in 1% goat serum
(1:200, Vector, BA-1000). The Vector Vectastain ABC kit (PK-4000) and ImmPACT and DAB
Peroxidase Substrate Kit (SK-4105-Reagent 1) were utilized to visualize positive cells. Images
were captured using the Aperio ScanScope slide scanner. The Aperio ScanScope slide scanner
was also used to measure high grade tumor areas.

Statistical analyses
In quantitative studies, each tested group were performed at least in triplicate. All graphs
and statistical tests of in vitro and in vivo studies were generated using GraphPad Prism 9. Column
data graphs are presented as mean ± standard deviation. To determine statistical differences of
multiple groups, we performed an ordinary one-way ANOVA. To determine statistical differences
of two groups, we performed a 2-tailed Student’s t-test, or the Tukey’s multiple comparisons test
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(which can be derived via the ordinary one-way ANOVA by selecting the option that compares
every mean with every other mean). P values < 0.05 were considered significant.
Statistical consideration and analyses for our survival studies are based on our preliminary
data, which indicated that survival in the control mice is roughly normally distributed with a
median of about 38 days and a standard deviation of about 11 days. The treated mice have a
standard deviation of about 22 days (since treated mice respond to varying degrees). Unless
otherwise stated, we used at least 10 mice per group based on computer simulations that
demonstrated roughly 91% power to detect 30 day differences in median survival between treated
and control groups (using a two-sided 1% alpha). We used Kaplan-Meier estimates to graph the
survival curves and performed the Log-rank Mantel-Cox test to assess for differences, where
P values < 0.05 were considered significant.
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Table 1: List of antibodies used in hexon titration, western blot, and flow cytometry
assays.
Hexon Titration
Catalog
Number

Dilution

Millipore

AB1056

1:500

Vector
Biolabs

BA-5000

1:500

Antibody Name Company
Goat AntiAdenovirus
Polyclonal
Antibody
Biotinylated
anti-goat IgG
(H+L)

Western blot
Antibody Name
Fiber:
Adenovirus
Type 2 Fiber
Antibody (4D2)
Adenovirus-2/5
E1A Antibody
α Tubulin
Antibody

Clone

Company

Catalog Number

Dilution

4D2

ThermoFisher

MA5-11222

1:1000

M73

Santa Cruz

sc-25

1:500

B-5-1-2

Santa Cruz

sc-23948

1:2000

Flow Cytometry: Regulatory T-Cell Panel
Marker

Clone

Fluorophore

Company

CD45

30-F11

APC-R700

BD Biosciences

Catalog
Dilution
Number
565478
1:100

CD3e

145-2C11

PerCP-Cy5.5

BD Biosciences

551163

1:100

CD4

RM4-5

V450

BD Biosciences

560468

1:100

CD8

53-6.7

BV510

BD Biosciences

563068

1:100

CD25

PC61

APC

BD Biosciences

1:100

FOXP3

FJK-16s

FITC

Invitrogen

FVS780

NA

BV780

BD Biosciences

557192
115773-82
563068
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1:100
1:1000

Flow Cytometry: MDSC Panel
Marker

Clone

Fluorophore

Company

CD45

30-F11

APC-R700

BD Biosciences

Catalog
Dilution
Number
565478
1:100

CD3e

145-2C11

PerCP-Cy5.5

BD Biosciences

551163

1:100

GR1

RB6-8C5

FITC

BD Biosciences

553126

1:100

CD11b

M1/70

APC

BD Biosciences

553312

1:100

FVS780

NA

BV780

BD Biosciences

563068

1:1000
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Chapter 3: Transcriptome analyses of Delta-24-RGDOX shows activation of IDO-related genes
and the triggering of immune activation and pro-inflammatory pathways.

Rationale and Expectations
A recent phase I study showed that the treatment of recurrent glioblastoma patients with
Delta-24-RGD resulted in about 20% of patients living past three years (90). Furthermore, the
exploratory objectives of this study showed that in addition to the anti-tumor effect of Delta-24RGD, a robust immune response was also elicited. This was evident in the H&E sections that
showed infiltration of immune cells within the tumor. Furthermore, immunohistochemical
analysis also showed infiltration of T-bet associated CD8+ T cells within the Delta-24-RGD
infected brain tumor, suggesting the Delta-24-RGD mediated activation of a Th1 mediated
immune response (90).
With the goal of improving the percentage of patients that respond to Delta-24-RGD, we
developed the next generation virus called Delta-24-RGDOX, which contains the cDNA of
immune agonist, OX40L (91). In addition to eliciting oncolysis, Delta-24-RGDOX can also
express OX40L on the tumor cell surface (91), enhancing the co-stimulation signal of activated T
cells to increase the number of clones that are activated within the tumor microenvironment (93).
The treatment of tumors with Delta-24-RGDOX should be able to stimulate both anti-viral
responses and increase the immune activating arm via the OX40L-OX40 pathway. Thus, we
hypothesized that Delta-24-RGDOX can dramatically reshape the microenvironment.
To test our hypothesis, we performed RNA sequencing analyses on GL261-5 mouse brain
tumors that were treated with PBS or Delta-24-RGDOX. To determine global gene expression
changes between the two groups, we generated a heat map of all differentially expressed genes.
Furthermore, we performed enrichment analyses of gene ontology biological processes to
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determine the differences between the untreated and Delta-24-RGDOX treated brain tumors.
Moreover, we performed ingenuity pathway analyses to determine the top five canonical and
upstream regulator pathways that were upregulated in response to Delta-24-RGDOX. Additional
analyses also determined the prediction of immune cell composition within the untreated and
treated brain tumors. Lastly, we explored the expression pattern of the IDO pathway.
Based on previous studies showing that Delta-24-RGDOX was more effective in
generating immune responses and curing murine GL261-5 brain tumor bearing mice (91), we
expected that in response to Delta-24-RGDOX, the Gl261-5 brain tumors would be dramatically
different compared to untreated brain tumors in terms of their global gene expression.
Furthermore, we expected that Delta-24-RGDOX would increase the immune responses, based
on our hypothesis that treatment of the tumors with the adenovirus will increase the
immunogenicity of the tumors (41). As such, we expected both immune activating and immune
suppressing pathways, including the IDO pathway, to increase in Delta-24-RGDOX treated brain
tumors.
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Results
Because RNA-seq allows an unbiased cellular and molecular profiling of complex tissues
in solid tumors, characterized by phenotypic alterations due the multicellular composition of the
cancer cells and the tumor microenvironment, we decided to perform RNA-sequencing analyses
of murine glioma tumors infected with Delta-24-RGDOX and control-treated tumors.
Delta-24-RGDOX reshapes the murine brain tumor microenvironment.
We observed that Delta-24-RGDOX treatment induced a powerful reshaping of the tumor
microenvironment (Figure 2). In comparison with control-treated tumors, Delta-24-RGDOXtreated tumors were enriched for populations related with inflammation and Th1 and Th17
immune response, including IFNγ, TNF, and IL-17 (Figure 3).
Delta-24-RGDOX increases the predicted diversity and percentage of immune populations.
While transcriptional signatures related to macrophages and dendritic cells remain
practically unchanged

by the Delta-24-RGDOX treatment,

major changes

in

the

microenvironment promoted by the infection included the remarkable increase of the CD8+ T
related transcriptome (P = 0.0031), which were practically absent in the control treated tumors,
and a trending in the upregulation of the NK transcriptional signature (P = 0.11). In addition, there
was a significant decrease in the predicted presence of CD4+ T cells (P = 0.0127) (Figure 4).
Delta-24-RGDOX induces expression of genes from the IDO pathway.
As expected, after viral infection, the tumors showed upregulation of the IDO circuitry, a
pathway targeted for virus and tumors to escape the immune system. IDO-related network of
genes that were upregulated after Delta-24-RGDOX treatment included TGFβ, CTLA-4, PD-1,
and GATA-3 (Figure 5).
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Figure 2: Delta-24-RGDOX reshapes the brain tumor microenvironment.
Differentially expressed genes in tumors treated with PBS versus tumors treated with
Delta-24-RGDOX are utilized for clustering or GO biological process. A) Heatmap
comparing the transcription signature of intracranial GL261-5-derived tumors treated with
PBS or Delta-24-RGDOX. The log2 normalized expression levels of genes with
significant adjusted P-value (<0.05) across samples are shown. Color scale is shown on
top of the heatmap. (B) Gene ontology (GO) biological process enrichment in tumors
treated with PBS or Delta-24-RGDOX. The five most significant (±) GO biological
processes are represented. GO biological processes significantly associated with PBS
treated tumors are marked as ‘+’, whereas those in Delta-24-RGDOX are marked as ‘-’.
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Figure 3: Delta-24-RGDOX increases both immune-activating and immune-suppressing
pathways.
Ingenuity pathway analyses of GL261-5 brain tumors treated with PBS or Delta-24-RGDOX.
(A) Five most significantly altered canonical pathways in tumors treated with PBS versus
Delta-24-RGDOX. Activation z-score are plotted in the graph. (B) Five most significantly
altered upstream regulators in tumors treated with PBS versus Delta-24-RGDOX. Activation
z-score are plotted in the graph. The –ve z-Score represent activation in Delta-24-RGDOX. †,
Hypercytokinemia/hyperchemokinemia in the Pathogenesis of Influenza; ††,
Neuroinflammation Signaling Pathway.
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Figure 4: Delta-24-RGDOX increases and diversifies the predicted immune cell
composition within the brain tumor microenvironment.
(A) The prediction of immune cell composition in GL261-5-derived brain tumors treated with
PBS or Delta-24-RGDOX. The percentages of various immune cell populations in each sample
are presented in the graph. The color code for various immune cell types is shown on the right
of the graph.
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A

Figure 5: Delta-24-RGDOX induces expression of genes from the IDO pathway.
A) IDO1 network genes with significantly altered expression levels in tumor treated with PBS
or Delta-24-RGDOX. The intensity of color depicts log2 fold change levels for each gene in
PBS vs. Delta-24-RGDOX treated tumors.
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Conclusions
Collectively, these results indicated that Delta-24-RGDOX induces a robust effect on the
immune response and that there was a double-edge activation of pathways that positively and
negatively regulate the immune response against virus and tumors. Among them, the infection
with Delta-24-RGDOX triggered the upregulation of the IDO circuitry.
Importantly, this data shows that the treatment of these murine brain tumors increases the
immunogenicity of the tumors, as indicated by the gene ontology biological processes analyses,
which showed the enrichment of cancer cell cycles pathways in the PBS treated tumors and the
contrasted enrichment of immune-related pathways in the Delta-24-RGDOX treated brain tumors.
Furthermore, the prediction of the immune cell composition also suggests that Delta-24-RGDOX
increases the diversity of various immune populations. Similarly, the ingenuity pathways analyses
showed the elicitation of immune pathways. In addition to this increase of immunogenicity, it is
noteworthy to mention that Delta-24-RGDOX does not only elicit immune activating pathways,
but also immune suppressing pathways, including the IDO pathway.
These results confirm our hypothesis that oncolytic adenoviruses can transform “cold”
tumors to “hot” tumors. This phenomenon was elegantly described by Sharma and Allison, which
states that this conversion of immunogenicity can increase the likelihood of tumors to respond to
immunotherapies (41). Complimentarily, the upregulation of the IDO pathway support our
rationale to combine IDO inhibitors with Delta-24-RGDOX for the treatment of glioma.
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Chapter 4: IFNγ or Delta-24-RGDOX infection induces IDO or AhR expression or activation
in vivo and in vitro in human glioma stem cells and murine glioma cells.

Rationale and Expectations
Indoleamine-2,3-dioxygenase (IDO) is upregulated in glioblastoma and correlates with a
poor prognosis (23). IDO is an enzyme that catabolizes tryptophan (Trp) into kynurenine (Kyn).
The production of Kyn causes immune toxicity of the tumor microenvironment. Kyn also acts as
a ligand to activate aryl hydrocarbon receptor (AhR) translocation into the nucleus, which can
elicit carcinogenesis and further immune suppression (27, 29). In the context of oncolytic
virotherapy, tryptophan depletion by IDO activation can hinder the generation of new virions,
reducing viral spread. IDO is inducible by stimuli that are related to viral infection (58), which
means that upon infection, generation of a positive IDO-Kyn-AhR pathway feedback loop can
occur that aids in decreased viral activity.
Several studies have identified IDO activation during the response to external-danger
stimuli, including pathogens, like viruses (27, 58, 160). Following viral infection, the main players
involved in IDO activation are pathogen-associated molecular patterns, damage-associated
molecular patterns, and the activation of interferons, all of which are important for the innate and
adaptive responses (27). Studies have shown that human immunodeficiency virus and influenza
infections induce IFNγ production (59, 66). Furthermore, one study found that HIV infection of
PBMCs in vitro leads to secretion of type I interferons, IFNα and IFNβ (61). Importantly, these
studies show that these interferons effect IDO expression and activation. Relatedly, reports have
shown that in addition to generation of pathogen associated molecular patterns, adenoviral
infections lead to type I and type II IFN responses, including IFNα or IFNβ, and IFNγ,
respectively (69-72). Important to our studies, IDO is an IFN-inducible protein (152).
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An important result of IFNα and IFNβ is its activation of the Janus family kinase-signal
transducer and activator of transcription (JAK-STAT) signaling cascade. The activation of the
JAK-STAT elicits host antiviral properties (161). In fact, the use of JAK1/2 inhibitor, Ruxolitinib,
can enhance replication in a measles virus-resistant human derived glioblastoma cell line (162).
JAK/STAT activation can also regulate IDO, and several studies have shown that inhibition of
the JAK-STAT pathway led to inhibition of IDO (reviewed in (163)). Thus, not only can IDO be
activated directly by IFN, but also via JAK-STAT signaling.
In summary, IDO is upregulated in glioblastoma and associates with a poor prognosis.
Furthermore, viral infection elicits several stimuli that are activators of IDO including, IFNα,
IFNβ, IFNγ, and JAK/STAT. This interplay between viral infection and IDO activation can
generate a positive feedback loop of the IDO pathway that can: 1) hinder viral replication and 2)
elicit mechanisms of immune suppression in oncolytic virus treated cancers.
We wanted to determine the effects of IFNγ and Delta-24-RGDOX in human and murine
glioblastoma cancer on IDO or AhR expression and activation in vivo and in vitro. Taking into
consideration the previously published literature of stimuli that lead to IDO and AhR activation,
we expected the following to occur in the cancer cells:
1) IFNγ will induce IDO expression.
2) Delta-24-RGDOX will induce IDO expression.
3) Delta-24-RGDOX will activate IDO via increased Kyn/Trp levels.
4) Delta-24-RGDOX will induce AhR expression.
5) Delta-24-RGDOX will activate AhR.
6) Delta-24-RGDOX will elicit AhR translocation into nucleus.
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Results
IFNγ induces IDO expression in human cancer cells.
IDO was the first known gene to be inducible by IFNγ (152). Because adenoviruses can
elicit an IFNγ response in vivo, we wanted to determine the effects of IFNγ on IDO expression in
a panel of human glioma stem cells (GSC) including NSC 11, GSC 7-2, and GSC20; we also used
HeLa cells as positive control. Figure 6 shows a significant increase in IDO mRNA levels in the
glioma stem cells treated with IFNγ.

Delta-24-RGDOX activates the AhR pathway in human cancer cells.
IDO is an enzyme that catabolizes Trp to Kyn, which can be aided by type I interferons,
IFNα and IFNβ. These IFNs can also be elicited in adenoviral infected cells. In turn, Kyn can
bind to transcription factor AhR to activate it, which has been shown to cause pro-tumorigenic
effects. (27, 42, 164, 165) Thus, we wanted to explore the activity of AhR in Delta-24-RGDOX
infected GSCs and HeLa cells; in Figure 7, we showed that there was an increase AhR activity
in NSC 11, GSC 7-2, GSC20, and HeLa cells in response to Delta-24-RGDOX infection.

Delta-24-RGDOX induces Ahr expression and translocation into the nucleus.
To further explore the activation of IDO by Delta-24-RGDOX, we studied the expression
of AhR in HeLa cells that were infected with Delta-24-RGDOX using immunofluorescence.
Figure 8A shows that Delta-24-RGDOX infected HeLa cells show an observable increase in AhR
expression within both the cytoplasm and nucleus compared to mock infected cells, indicating the
translocation of AhR to the nucleus induced by Delta-24-RGDOX. Quantification of these results,
as seen in Figure 8B-D, showed increase of nuclear AhR intensity, whole cell AhR intensity, and
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the frequency of AhR positive cells compared to mock treated cells. These data were
complemented with HeLa cells treated with Kyn, which acted as our positive control.

IFNγ, Delta-24-RGD, or Delta-24-RGDOX induces IDO expression in vitro and in vivo in murine
models of cancer.
IDO expression was also inducible by IFNγ or Delta-24-RGDOX in murine glioma cells,
GL261-5 and GSC-005. When these cell lines were treated with IFNγ or Delta-24-RGDOX, IDO
mRNA significantly increased compared to mock infected cells, as seen in Figure 9A. To test the
impact of viral infection on IDO expression in vivo, we treated GL261-5- bearing mice with Delta24-RGD or Delta-24-RGDOX and collected their brain tumors 24 h after the last virus dose for
analysis of IDO expression by qRT-PCR. Figure 9B shows that Delta-24-RGD increased IDO
mRNA in the GL261-5 model compared to PBS treated mice, and that Delta-24-RGDOX
increased IDO mRNA expression even further. Furthermore, we showed that Delta-24-RGDOX
significantly increased IDO mRNA in the murine 4T1.2 breast cancer model, as seen in Figure
9C, and that IDO expression decreased with the treatment of Trp-mimetic, Indoximod.

Delta-24-RGD or Delta-24-RGDOX induces IDO activation in of murine glioblastoma models.
Next, we wanted to determine IDO activity in PBS, Delta-24-RGD, or Delta-24-RGDOX
treated brain tumor bearing mice by measuring the Kyn to Trp ratio by LC-MS. An active IDO
will catabolize tryptophan and generate an excess of Kyn, therefore a relatively high Kyn to Trp
ratio indicates IDO activity. As seen in Figure 10, both the GL261-5 and GSC-005 murine brain
tumor models showed that Delta-24-RGD infection increased IDO activity compared to PBS
treated mice, as indicated by the increase in the Kyn to Trp ratio. The Kyn to Trp ratio further
increased in the mice that were infected with Delta-24-RGDOX.
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Figure 6: IFNγ induces IDO expression in human glioma stem cells and HeLa cells.
Cells were untreated (Mock) or treated with 200 u/mL of IFNγ for 24 hours. RNA was
extracted and relative levels of IDO was measured using qRT-PCR; GAPDH or β-Actin were
used as housekeeping gene controls. The column graphs show 2^(CtGAPDH or β-Actin-CtIDO)
normalized to the Mock control.
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Figure 7: Delta-24-RGDOX activates AhR in human glioma stem cells and HeLa cells.
The figure shows AhR activity of a human GSC lines and HeLa cells in response to Delta24-RGDOX. These cells were untreated (Mock) or infected with 50 MOI of Delta-24RGDOX and incubated for 48 hours; the supernatants were used in a commercially available
Human Aryl Hydrocarbon Receptor (AhR) assay kit (INDIGO Biosciences), which uses AhR
Reporter Cells that give off a luminescent signal when AhR is activated. Controls included
media (negative), media containing MeBio (positive), an AhR agonist, and media containing
Kynurenine (Kyn-positive), an activator of the Ahr Pathway.
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Figure 8: Delta-24-RGDOX induces AhR expression and translocation into the nucleus.
HeLa cells were untreated (Mock), treated with Kyn (positive control), or infected with 25
MOI of Delta-24-RGDOX, incubated for 48 hours, and then stained with AhR using
immunofluorescence. The microscopy images (A) show cells stained with Ahr-FITC, DAPI,
and merged FITC/DAPI. Scale bar, 50 µm. The column graphs represent quantification of
(B) nuclear AhR intensity, (C) whole cell AhR intensity, and (D) frequency of AhR positive
cells (analyzed using ImageJ software).
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Figure 9: IFNγ, Delta-24-RGD, or Delta-24-RGDOX induces IDO expression in cancer
cells in vivo and in vitro.
Panel (A) shows relative IDO expression murine glioma cells in response to IFNγ or Delta24-RGDOX. Cells were untreated (Mock), treated with 200 u/mL of IFNγ, or infected with
Delta-24-RGDOX for 48 hours at indicated MOIs. RNA was extracted and relative levels of
IDO was measured using qRT-PCR; GAPDH or β-Actin were used as housekeeping gene
controls. The column graphs show 2^(CtGAPDH or β-Actin-CtIDO) normalized to the Mock control.
Panel (B) shows relative IDO expression in GL261-5 brain tumors in response to Delta-24RGD or Delta-24-RGDOX infection. Mice were bolted on day -7, then implanted with 5 x
104 GL261-5 cells on day 0; on days 7, 9, and 11, the mice were intratumorally injected with
PBS, Delta-24-RGD (5 x 107 pfu/dose), or Delta-24-RGDOX (same dose). Mouse brain
tumors were collected on day 12, cut in half and flash frozen for RNA extraction. The column
graph shows relative IDO expression of the differently treated brain tumors using 2^(Ctβ-ActinCtIDO) normalized to the PBS treated mice. Panel (C) shows the relative IDO expression of
4T1.2 bearing mice treated with PBS, Delta-24-RGDOX, or Indoximod. Mice were
implanted with 1 x 104 4T1.2 cells in the right mammary fat-pad on day 0, injected with PBS
or Delta-24-RGDOX (1 x 108 pfu/mouse) on days 10, 14, 16, 18, and 21, or treated with
Indoximod on days 10-35 (275 mg/kg, BID). The 4T1.2 breast tumors were flash frozen on
day 36 and extracted for RNA and quantified for IDO mRNA using the above methods.
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Figure 10: Delta-24-RGD or Delta-24-RGDOX activates the IDO pathway in murine
gliomas.
Mice were bolted on day -7, then implanted with 5 x 104 GL261-5 or GSC-005 cells on day
0; on days 7, 9, and 11 (GL2621-5), or days 9 and 11 (GSC-005), the mice were intracranially
injected with PBS, Delta-24-RGD (5 x 107 (GL261-5) or 1.25 x 107 (GSC-005) pfu/dose), or
Delta-24-RGDOX (same doses). Mouse brain tumors were collected on day 12, cut in half
and flash frozen for analysis of Kyn/Trp by LC-MS. The column graphs are showing (A/B)
the ratio of Kyn to Trp within the tumor microenvironment of PBS, Delta-24-RGD, or Delta24-RGDOX infected brain tumors measured by LC/MS of the (A) GL261-5 or (B) GSC-005
murine brain tumor model.
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Conclusions
To support previous findings that viral infections generate different stimuli to induce
expression and activation of IDO and AhR, we performed in vitro and in vivo studies testing
expression and activation of both proteins induced by IFNγ or Delta-24-RGDOX.
We demonstrated that IFNγ induces expression of IDO in human glioma cells and HeLa
cells. Delta-24-RGDOX induces AhR activation in these same cells. We speculate that this
induction of AhR expression and activation could be due to responses by type I IFNs, IFNα and
IFNβ, or JAK-STAT signaling, all of which are viral-induced stimulators of IDO. This result
indirectly indicates that Delta-24-RGDOX activates IDO, since Kyn, a product of IDO enzyme
activity, is an activator of AhR.
Additionally, Delta-24-RGDOX increased the expression of AhR in the cytoplasm and
nucleus in HeLa cells, indicating the translocation of AhR into the nucleus by Delta-24-RGDOX.
The translocation of AhR into the nucleus indicates activation, as this relocation leads to
transcription of AhR target genes, which are involved in both tumorigenesis and generation of
immunosuppression of surrounding immune cells (29).
Complementarily, IFNγ and Delta-24-RGDOX also induced expression of IDO in murine
cancer cell lines. These data were accompanied with the increased expression and activation (via
increased Kyn/Trp ratios) of IDO in Delta-24-RGD and Delta-24-RGDOX treated mouse brain
tumors.
Overall, these results suggested that increased expression and activation of proteins from
the IDO-Kyn-AhR cascade results from oncolytic adenoviral infection, which could hinder antitumor viral responses via immunosuppression. These results suggest that IDO is a proper
therapeutic target and that IDO inhibitors can be combined with oncolytic adenoviruses, such as
Delta-24-RGDOX to enhance the anti-glioma effect of virotherapy.
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Chapter 5: Inhibition of IDO does not hinder Delta-24-RGDOX infection, replication, or viralinduced cytopathic ability in human and murine glioma cells.

Rationale and Expectations
Several studies demonstrated the role of the IDO pathway in attenuating the replication of
pathogens such as cytomegalovirus, measles, herpes simplex virus, and vaccinia virus (166-169).
It is important to mention that the effect of IDO was due, at least in part, to the depletion of Trp,
because adding supra-physiological levels of exogenous Trp restored viral replication (170).
The depletion of Trp by an activated IDO is directly correlated to the production of the
metabolite Kyn, which is an activating ligand of AhR. Emerging data have shed light on an
unexpected role of the ligand-activated transcription factor AhR in transducing the function of
IDO in cancer cells (30). Of interest, the AhR pathway modulates the expression of the cell cycle
regulators p27 and p21 at the transcriptional level (171). These cyclin-dependent kinase inhibitors
negatively regulate progression of the cell cycle by inducing G1 and G2 arrest and, thus,
restricting the virus access to the S-phase machinery required for viral DNA replication (80, 172).
In fact, in experiments performed by other laboratories, deletion of p27 or p21 were shown to
facilitate the replication and oncolytic effect of Delta-24 (173).
Based on these observations, we hypothesized that activation of the IDO molecular
pathway will attenuate the anti-glioma effect of Delta-24-RGDOX by both depleting the infected
cells of the essential amino acid tryptophan and inducing AhR-mediated upregulation of the
potent inhibitors of cell cycle progression, p21 and p27.
Since we have shown the expression and activation of both IDO and AhR in response to
Delta-24-RGDOX in vitro in human and murine glioma cell lines, we expected that there would
be enhancement of viral activity in the presence of an IDO inhibitor. Thus, to test our hypothesis,
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we employed the cell lines, GL261-5, GSC 8-11, GSC 13, GSC 20, and GSC-005, and infected
them with Delta-24-RGDOX with or without IDO inhibitor treatment using either BGB-7204
(direct IDO enzyme inhibitor) or Indoximod (Trp mimetic) and measured viral replication via a
hexon titration, expression of viral proteins fiber and E1A, and viral-induced cytopathic ability
via a commercially available cell viability kit. Based on data from previous publications and
results from our studies from Chapter 4 we expected the following:
1) In the GL261-5 cell line, we did not expect Delta-24-RGDOX to replicate, since
we have shown in the past that this cell line is does not permit replication of the
adenovirus (91). As such, we did not expect any changes in viral activity of Delta24-RGDOX in GL261-5 that were also treated with an IDO inhibitor. This cell line
served as our negative control.
2) Viral activity, including replication, expression of fiber, and viral-induced
cytopathic ability of Delta-24-RGDOX will occur in replication-permissive cell
lines, GSC-8 GSC 8-11, GSC 13, GSC 20, and GSC-005. This viral activity will
be enhanced when these cell lines are also treated with an IDO inhibitor.

58

Results
To ascertain the effect of IDO activity on virus activity, we studied viral infection, viral
replication, and viral-induced cytopathic ability of Delta-24-RGDOX in GL261-5, GSC 8-11,
GSC 13, GSC 20, and GSC-005 with or without IDO inhibition using either BGB-7204 or
Indoximod. BGB-7204 is a direct IDO enzyme inhibitor (provided by Dr. Derek Wainwright,
Northwestern University, Feinberg School of Medicine). Indoximod is a Trp-mimetic that can
provides an artificial supplement of Trp.
As we expected, mouse glioma cell line, GL261-5, our negative control, did undergo
infection by Delta-24-RGDOX, as indicated by clear expression of viral infection protein, E1A,
but was not capable of viral replication (Figure 11A and 11B, respectively). Still, after infection
with a high multiplicity of infection (MOI), the GL261-5 cells endured substantial viral-induced
cell death over time (Figure 11C). When we infected GL261-5 with Delta-24-RGDOX in the
presence of an IDO inhibitor (either BGB-7204 or Indoximod), the infection, viral replication,
and viral-induced cytopathic ability remained unchanged compared to Delta-24-RGDOX
infection alone (Figure 11).
Contrary to our expectations, Figure 12A shows that Delta-24-RGDOX replication via
hexon titration levels were unchanged when BGB-7204 was added to the cultures of human GSC
8-11, GSC 13, and GSC 20 glioma cells. Similarly, as seen in Figure 12B, the expression of viral
replication protein, fiber, was unchanged and viral infection protein, E1A, was still present when
we added BGB-7204 to Delta-24-RGDOX infected cultures. Correspondingly, the viral-induced
cytopathic ability was unchanged when we added BGB-7204 to Delta-24-RGDOX infected
cultures, as seen in Figure 12C.
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Notably, the GSC-005 cell line showed enhancement of viral replication by hexon
titration, fiber expression, and viral-induced cytopathic ability of Delta-24-RGDOX in the
presence of BGB-7204, as seen in Figures 13A-C.
These results suggest that viral function of Delta-24-RGDOX remains unchanged and can
be enhanced with IDO inhibitors.
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Figure 11: Inhibiting IDO does not alter Delta-24-RGDOX infection, replication, or
viral-induced cytopathic ability in murine GL261-5 glioma cells.
GL261-5 cells were tested for Delta-24-RGDOX infection, replication, and viral-induced
cytopathic ability with or without IDO inhibition. Cells were untreated (Mock), infected with
UV-inactivated Delta-24-RGDOX, infected with Delta-24-RGDOX at 150 MOI, or treated
with combined Delta-24-RGDOX and IDO inhibitor, BGB-7204 or Indoximod, at indicated
concentrations. Panel (A) shows viral replication of Delta-24-RGDOX or combined Delta24-RGDOX and BGB-7204 or Indoximod. The column graph shows the log concentration of
the virus (pfu/mL). The cyan bar represents the initial concentration of Delta-24-RGDOX,
and the subsequent bars show the concentration of Delta-24-RGDOX or combined Delta-24RGDOX and BGB-7204 or Indoximod after infection of the cells for 48 hours, which was
measured using a hexon titration assay in 293 cells. Panel (B) shows expression of viral
infection protein, E1A, under different treatments. The cells were treated with the indicated
treatment for 48 hours, and proteins were extracted and blotted for E1A and tubulin. Panel
(C) shows viral-induced cytopathic ability of Delta-24-RGDOX or combined Delta-24RGDOX and BGB-7204 or Indoximod. The cells were seeded in a 96 well plate and
appropriately treated up to 120 hours, and viral-induced cytopathic effects was measured
every 24 hours using the commercially available ViralToxGlo Assay (Promega), which
quantifies cell viability via ATP levels. The graph shows the percent viability normalized to
the mock infected cells.
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Figure 12: Inhibiting IDO does not alter Delta-24-RGDOX infection, replication, and
viral-induced cytopathic ability in human glioma stem cells.
Patient-derived human glioma cells, GSC-11, GSC-13, and GSC-20 were tested for Delta24-RGDOX infection, replication, and viral-induced cytopathic ability with or without IDO
inhibition. Cells were untreated (Mock), infected with UV-inactivated Delta-24-RGDOX,
infected with Delta-24-RGDOX at 25 MOI, or treated with combined Delta-24-RGDOX and
IDO inhibitor, BGB-7204, at 150nM. Panel (A) shows viral replication of Delta-24-RGDOX
or combined Delta-24-RGDOX and BGB-7204 of the indicated cell line. The column graph
shows the log concentration of the virus (pfu/mL). The cyan bar represents the initial
concentration of Delta-24-RGDOX, and the subsequent bars show the concentration of
Delta-24-RGDOX or combined Delta-24-RGDOX and BGB-7204 after infection in the
indicated cell line for 48 hours, which was measured using a hexon titration assay in 293
cells. Panels (B) shows expression of viral replication protein, fiber, and viral infection
protein, E1A, in Delta-24-RGDOX or combined Delta-24-RGDOX and BGB-7204 treated
cells. The cells were treated with the indicated treatment for 48 hours, and proteins were
extracted and blotted for fiber, E1A, and tubulin. Panel (C) shows viral-induced cytopathic
ability of Delta-24-RGDOX or combined Delta-24-RGDOX and BGB-7204 in indicated
cells. The indicated cell lines were seeded in a 96 well plate and appropriately treated up to
168 hours, and viral-induced cytopathic effects was measured every 24 hours using the
commercially available ViralToxGlo Assay (Promega), which quantifies cell viability via
ATP levels. The graph shows the percent viability normalized to the mock infected cells.
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Figure 13: Inhibiting IDO enhances Delta-24-RGDOX replication and viral-induced
cytopathic ability in murine glioma stem cell line, GSC-005.
Murine glioma cell line, GSC-005, was tested for Delta-24-RGDOX infection, replication,
and viral-induced cytopathic ability with or without IDO inhibition. Cells were untreated
(Mock), infected with UV-inactivated Delta-24-RGDOX, infected with Delta-24-RGDOX at
100 MOI, or treated with combined Delta-24-RGDOX and IDO inhibitor, BGB-7204, at
50nM. Panel (A) shows viral replication of Delta-24-RGDOX or combined Delta-24RGDOX and BGB-7204. The column graph shows the log concentration of the virus
(pfu/mL). The cyan bar represents the initial concentration of Delta-24-RGDOX, and the
subsequent bars show the concentration of Delta-24-RGDOX or combined Delta-24-RGDOX
and BGB-7204 after infection for 48 hours, which was measured using a hexon titration assay
in 293 cells. Panel (B) shows expression of viral replication protein, fiber, and viral infection
protein, E1A, in Delta-24-RGDOX or combined Delta-24-RGDOX and BGB-7204 treated
cells. The cells were treated with the indicated treatment for 48 hours, and proteins were
extracted and blotted for fiber, E1A, and tubulin. The ratio of fiber/tubulin were acquired by
finding the ratio of pixels of fiber and tubulin using Image J software. Panel (C) shows viralinduced cytopathic ability of Delta-24-RGDOX or combined Delta-24-RGDOX and BGB7204 of the cells. The cells were seeded in a 96 well plate and appropriately treated up to 96
hours, and viral-induced cytopathic effects was measured every 24 hours using the
commercially available ViralToxGlo Assay (Promega), which quantifies cell viability via
ATP levels. The graph shows the percent viability normalized to the mock infected cells.
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Conclusions
In Chapter 4, we established the induction of IDO or AhR expression or activation in
response to Delta-24-RGDOX infection in vitro. As such, we initially believed that blockade of
IDO in vitro in Delta-24-RGDOX infected human and murine glioma cells would enhance viral
activity, on the basis that IDO blockade would decrease Trp depletion and reverse potential AhR
inhibitory effects of cell cycle progression (171).
Interestingly, in the GSC-005 cell line, viral replication and viral-induced cell death
induced by Delta-24-RGDOX increased in the presence of an IDO inhibitor. However, when we
infected GSC8-11, GSC13, and GSC20 with Delta-24-RGDOX in the presence of an IDO
inhibitor, we observed no changes in viral replication or viral-induced cytopathic ability compared
to Delta-24-RGDOX infection alone. The results from the human glioma stem cells mirrored the
result of our negative control, GL261-5. Still, it is noteworthy to mention that even with treatment
with these IDO inhibitors, the viral activity is maintained, strengthening our rationale that IDO
inhibitors are a good candidate to be combined with Delta-24-RGDOX.
This result is important because it shows that there are no unwanted drug interactions
between the virus and the IDO inhibitors. Furthermore, these contrasting results between GSC005 and the other cell lines underscore the complexity of viral activity in the context of the IDOKyn-AhR pathway.
In conclusion, treatment of murine and human glioma cells with an IDO inhibitor has no
effect or a positive effect on adenovirus replication suggesting that adding IDO inhibitors with
oncolytic adenoviruses will not result in detriment of the effect of virotherapy.
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Chapter 6: Survival advantage in IDO-KO mice treated with Delta-24-RGDOX compared to
WT mice.

Rationale and Expectations
In the previous chapters, we demonstrated that Delta-24-RGDOX infection of cancer cells
induces expression and activation of IDO and AhR. This suggests that despite the anti-tumor
responses we can generate using Delta-24-RGDOX, immunosuppression can still be maintained
by an active IDO and AhR. We additionally showed that inhibiting IDO in cancer cell cultures
infected with Delta-24-RGDOX does not alter viral replication or viral-induced cytopathic ability.
Our previous studies proved that glioma bearing mice treated with Delta-24-RGDOX
survive longer than mice treated with PBS (91). To ensure that the therapeutic effect of Delta-24RGDOX is maintained under IDO blockade, we tested the survival in glioma bearing C57BL/6
IDO-knock out (KO) (Jackson Laboratory) mice treated with PBS or Delta-24-RGDOX. Based
on our in vitro data showing that viral activity of Delta-24-RGDOX is maintained when we inhibit
IDO, we expected the following:
1) All glioma bearing IDO-KO mice treated with PBS will die.
2) Glioma bearing IDO-KO mice treated with Delta-24-RGDOX will have a longer
durable survival compared to PBS-treated mice.
In addition to determining if the therapeutic efficacy of Delta-24-RGDOX is maintained
in IDO-KO mice, we also wanted to ascertain whether targeting IDO in combination with Delta24-RGDOX would provide enhanced therapeutic responses in glioma bearing mice. More
specifically, to dissect any potential off-target effects of the IDO inhibitors that might mask the
predominant effects on the anti-tumoral immunity induced by the proposed therapy of combined
Delta-24-RGDOX and IDO inhibitor, we tested the anti-glioma effect of Delta-24-RGDOX using
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IDO-KO mice. In doing so, we were also able to determine the feasibility of combining IDO
inhibitors with Delta-24-RGDOX for the treatment of murine glioblastoma.
IDO is also involved in numerous immunosuppressive mechanisms, such as the
differentiation of naïve CD4+ T cells into the immunosuppressive regulatory T cell and the
induction T effector anergy or apoptosis via Trp depletion (27). Thus, by testing the anti-glioma
effect of Delta-24-RGDOX in IDO-KO mice and comparing them to wild-type (WT) mice using
IDO-WT glioma models, we can generalize the IDO effects of the host immune system and its
relationship to therapeutic responses. Based on these immunosuppressive mechanisms employed
by IDO, the IDO-KO mice should have decreased immunosuppressive mechanisms.
We expected the following results:
1) All glioma bearing mice treated with PBS will die regardless of genotype.
2) The deficient function of IDO in IDO-KO mice will enhance the therapeutic
efficacy of Delta-24-RGDOX against glioma, leading to longer and more durable
survival compared to WT mice.
3) These experiments will offer strong evidence that the effects of the IDO inhibitors
are justified by their effects on the respective targets.
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Results
Delta-24-RGDOX prolongs survival of IDO-KO glioma bearing mice.
Our previous in vitro results indicated that the inhibition of IDO did not alter viral
replication or viral induced cytopathic ability. To validate that inhibition of IDO still allows for
an oncolytic ability in vivo, we monitored the survival of IDO-KO C57BL/6 mice (The Jackson
Laboratory) bearing GL261-5 brain tumors after treatment with either PBS or Delta-24-RGDOX.
As seen in Figure 14, we demonstrated the oncolytic effect of Delta-24-RGDOX under the
extreme case of IDO inhibition via the IDO KO mice, as indicated by the significant delay in
median days of survival (55 vs 41.5 days, p = 0.0006) and presence of more long-term survivors
compared to PBS treated mice (30% vs 0%, p = 0.0006).

Glioma bearing mice of the IDO-KO genotype survive longer than the WT genotype when treated
with Delta-24-RGDOX.
We then wanted to ascertain whether the survival of glioma bearing mice can be enhanced
in IDO-KO mice compared to WT mice when treated with Delta-24-RGDOX. Thus, we used WT
or IDO-KO C57BL/6 mice, implanted them with GSC-005 cells, and treated them intratumorally
with either PBS or Delta-24-RGDOX. As seen in Figure 15, expectedly, all the PBS treated mice
died, regardless of genotype (p = 0.6967). Interestingly, the IDO-KO mice had a longer median
survival (107.5 vs 55 days, p = 0.0028) and more long-term survivors (20% vs 11.1%, p = 0.0028)
compared to WT mice when treated with Delta-24-RGDOX. These data corroborate our in vitro
data of Figure 13, which showed that in the GSC-005 model, viral activity, including replication
and viral-induced cytopathic ability increased in the presence of IDO inhibition by BGB-7204.
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Figure 14: Delta-24-RGDOX prolongs survival of IDO-KO glioma bearing mice.

Panel (A) shows the treatment scheme of this survival study. IDO-KO C57BL/6 mice were
4
bolted on day -7, followed by an implantation of 5x10 GL261-5 cells on day 0. On day 7,
mice were split into their respective groups, including PBS or Delta-24-RGDOX treatments.
7
When applicable, mice received an intratumoral injection of Delta-24-RGDOX (2.5 x 10
pfu/dose) on days 7, 9, and 11. Survival was monitored over 100 days. Panel (B) shows a
survival plot of IDO-KO mice bearing GL261-5 tumors treated with PBS (n=10) or Delta24-RGDOX (n=11). I.T., intratumoral.

68

A
GSC-005 IDO-KO Survival Study
Bolting
5x10^4 GSC-005 I.C. Injection
Delta-24-RGDOX I.T. Injection
Monitor Survival
Day: -7

B

0

7

14

21

GSC-005 Brain Tumor Bearing Mice
Percent Survival

100
75
50
25
0
0

50

100

150

200

Days Elapsed
p=0.6967
p=0.0028

WT: PBS
IDO-KO: PBS
WT: Delta-24-RGDOX

p=0.0001

IDO-KO: Delta-24-RGDOX

p=0.0142

log-rank test, p > 0.05 is ns

Figure 15: Glioma bearing mice of the IDO-KO genotype survive longer than the WT
genotype when treated with Delta-24-RGDOX.
Panel (A) shows the treatment scheme of this survival study. Mice were bolted on day -7,
4
followed by an implantation of 5x10 GSC-005 cells on day 0. On day 7, mice were split into
their respective groups including PBS or Delta-24-RGDOX treatments in either WT or IDOKO C57BL/6 mice. When applicable, mice received an intratumoral injection of Delta-247
RGDOX (2.5 x 10 pfu/dose) on days 7, 9, and 11. Survival was monitored over 200 days.
Panel (B) shows a survival plot of IDO-KO or WT mice bearing GSC-005 tumors treated
with PBS (WT, n=6; IDO-KO, n=8) or Delta-24-RGDOX (WT, n=9; IDO-KO, n=10). I.C.,
intracranial. I.T., intratumoral.
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Conclusions
The oncolytic and therapeutic effect of armed oncolytic adenoviruses, including Delta-24RGDOX, in glioma-bearing mice has been proven in our lab many times (91, 94, 174). First, to
ensure the therapeutic effect of Delta-24-RGDOX during on-target IDO blockade, we implanted
IDO-KO mice with murine glioma cells and treated them with PBS or Delta-24-RGDOX. Here,
Delta-24-RGDOX treated mice survived longer than PBS treated mice in glioma bearing IDOKO mice, suggesting that the oncolytic ability of Delta-24-RGDOX maintains its therapeutic
effects against murine glioma under IDO depletion.
Next, to strengthen our rationale to combine IDO inhibitors with Detla-24-RGDOX for
the treatment of glioma, we compared the survival of IDO-KO mice to WT mice bearing gliomas
that were treated with either PBS or Delta-24-RGDOX. The utilization of the IDO-KO mice
provides a precise evaluation of the on-target blockade of the IDO pathway combined with Delta24-RGDOX. This experiment revealed that the IDO-KO mice have a survival advantage over WT
mice when treated with Delta-24-RGDOX. This study also suggests that the effect of IDO
immunosuppression is generated from the host immune system, rather than the glioma cells, and
that targeting IDO in addition to treatment with Delta-24-RGDOX would be beneficial.
Additionally, this result of increased survival of the IDO-KO mice compared to the WT mice
suggest that the enhanced therapeutic effect is from the on-target inhibition of IDO.
Altogether, these data demonstrate the role of IDO as a negative regulator of the Delta24-RGDOX-mediated anti-glioma effect and supports the therapeutic use of IDO inhibition
during oncolytic virotherapy in glioma.
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Chapter 7: Treatment of brain tumor-bearing mice with the combination of IDO inhibitors and
Delta-24-RGDOX results in a survival advantage over single agent treatments and induces antiglioma immune memory.

Rationale and Expectations
Data from our clinical trials (175) and preclinical mechanistic studies (91, 94, 174) suggest
that the Delta-24-RGD and Delta-24-RGDOX infection of cancer cells elicits an immune response
against the virus that eventually shifts to an anti-tumor immune response, providing the rationale
to use immunomodulators as adjuvants to enhance the anti-tumor immune component of the
virotherapy.
IDO gained the interest of oncologists as a targetable pathway in different malignancies,
including malignant gliomas (23, 27, 30, 39, 40, 52, 57). Several pre-clinical studies have shown
that IDO inhibitors enhance the therapeutic effects of chemotherapy, cancer vaccines, or
immunotherapy (18, 48-51). For that reason, clinical trials are underway to test the triple
combination of IDO and PD-1 inhibitors with chemotherapy (NCT03661320) or with cancer
vaccines (NCT03519256).
There is a strong rationale for combining oncolytic viruses and IDO inhibitors: a) IFN is
the main response against adenoviruses such as Delta-24-RGDOX, and IDO is an IFNresponsive gene (152); b) IDO activity is a major response of the host cell against pathogens,
including viral infections (166-169), and c) IDO is found overexpressed in many malignancies
including glioblastoma (23) and activated in the course of viral infections (166-169). Consistent
with these previously published observations, we proved in the current study that IFNγ induced
IDO expression and that Delta-24-RGDOX induced expression and activation of IDO and AhR
in human or murine glioma cells. Gathering all this data, we expected that the combined Delta71

24-RGDOX and IDO inhibitor treatment would enhance survival of glioma bearing mice
compared to single agent treatments. More specifically, we expected the following:
1) Brain tumor-bearing mice treated with combined Delta-24-RGDOX and IDO
inhibitor will have longer and more durable survival compared to glioma bearing mice
treated with Delta-24-RGDOX or the IDO inhibitor alone.
2) The histopathological staining will show that the mice treated with combined Delta24-RGDOX and IDO inhibitor will have the smallest tumor mass compared to either
single agent treatment.
3) Long term survivors that were previously treated with the combined Delta-24RGDOX and IDO inhibitor will generate immune memory against the glioma and have
protection against a secondary glioma implantation.

72

Results
Delta-24-RGDOX combined with Trp-mimetic, 1MT or Indoximod, leads to smaller tumor mass,
provides a greater survival advantage, and induces a more robust anti-tumor immunity than
single agents in the treatment of solid tumors.
To determine the therapeutic efficacy of Delta-24-RGDOX combined with IDO inhibitors,
we performed a survival study using the immunocompetent GL261-5 C57BL/6 mouse model. As
shown in Figure 16A, a metal bolt was placed into the right skull directly above the caudate
nucleus of each mouse under anesthesia, and 7 days later, 5 × 104 GL261-5 cells were implanted
through the metal bolt. Starting on day 7 after tumor implantation, mice were split into 4 treatment
groups: 1) intracranial (I.C.) PBS and PBS by oral gavage, 2) I.C. PBS and 1MT or indoximod
by oral gavage, 3) I.C. Delta-24-RGDOX and PBS by oral gavage, and 4) I.C. Delta-24-RGDOX
and 1MT or indoximod by oral gavage. Mice treated with Delta-24-RGDOX were infected on
days 7, 9, and 11 at a dose of 5 × 107 pfu/mouse. Mice treated with 1MT or indoximod were
treated twice daily, 5 days/week, for 28 days, starting 7 days after tumor implant. As shown in
Figure 16B, the control mice and mice treated with 1MT alone had similar survival patterns, with
median survival times of 38.5 and 37.5 days, respectively (p > 0.9999). As expected, the mice
treated with Delta-24-RGDOX alone had significantly prolonged survival, with a median survival
time of 46.5 days and 20% of the mice surviving for at least 120 days (vs. control, p=0.02; vs.
Delta-24-RGDOX plus 1MT, p=0.01). Interestingly, mice treated with the combination of Delta24-RGDOX and 1MT had the longest survival, with a median survival time of 108.5 days and
50% of the mice surviving for at least 120 days (vs. control, p<0.0001; vs. Delta-RGDOX alone,
p=0.01). Furthermore, in mice treated with the combination of Delta-24-RGDOX and Indoximod,
hematoxylin-eosin staining revealed an observable and substantial tumor regression on day 15
and complete eradication by day 24 (Figure 17A), which was associated with the lowest surface
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areas of high-grade cellularity (Delta-24-RGDOX vs Delta-24-RGDOX and Indoximod, 2.10 x
106 vs. 0.44 x 106, p= 0.0298) (Figure 17B). H&E images of individual mice are seen in Figure
18. To confirm that the anti-tumor effect was immune mediated, the long-term survivors in the
group treated with Delta-24-RGDOX plus 1MT were re-challenged with the same glioblastoma
cell line and observed for survival. Importantly, all the mice previously treated with Delta-24RGDOX plus 1MT survived for at least 100 days, while all the untreated mice died by day 51
(p=0.0018) (Figure 16C). These data demonstrated the generation of memory against the tumor
by the combination of Delta-24-RGDOX and 1MT.
We also observed an enhanced survival effect using the B16-F10 intracranial melanoma
model, in which 14% of mice treated with Delta-24-RGDOX and Indoximod survived for at least
26 days, compared to zero survivors in the Delta-24-RGDOX only treated group (p = 0.0140,
Figure 19).
These results indicated that the combination of Delta-24-RGDOX and Trp-mimetics was
therapeutically superior to either treatment alone in mouse models of aggressive intracranial brain
tumors.

Delta-24-RGDOX combined with the direct IDO enzyme inhibitor, BGB-7204, leads to lower
tumor mass and provides a greater survival advantage compared to single agents in murine
glioblastoma.
Because 1MT and Indoximod are Trp-mimetics, they are not considered direct IDO
enzyme inhibitors. Thus, we also tested the therapeutic effect of Delta-24-RGDOX in the context
of direct IDO enzyme inhibition using BGB-7204 (provided by Dr. Derek Wainwright). BGB7204 is a novel pre-clinical direct IDO enzyme inhibitor that has shown therapeutic efficacy when
combined with radiation and anti-PD-1 monoclonal antibodies in murine models of glioma (57).
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We tested the antitumor effects in GSC-005 glioma bearing mice and submitted them to four
different treatment groups included treatment groups: 1) I.C. PBS and vehicle by oral gavage
(control), 2) I.C. PBS and BGB-7204 by oral gavage 3) I.C. Delta-24-RGDOX and vehicle by
oral gavage, and 3) I.C. Delta-24-RGDOX and BGB-7204 by oral gavage. Mice treated with
Delta-24-RGDOX were infected on days 9 and 11 at a dose of 2.5 × 107 pfu/mouse. Mice treated
with BGB-7204 were treated twice daily, 5 days/week, for 28 days starting on day 7. In mice
treated with the combination of Delta-24-RGDOX and BGB-7204, hematoxylin-eosin staining
revealed complete eradication by day 24 (Figure 20A), which associated with the lowest surface
areas of high-grade cellularity compared to all other treatment groups (Delta-24-RGDOX vs
Delta-24-RGDOX and BGB-7204, 7.64 x 105 vs. 0.42 x 105, p = 0.0261) (Figure 20B). H&E
images of individual mice are seen in Figure 21. These results indicated that the combination of
Delta-24-RGDOX and an IDO inhibitor was reproducible in a third murine glioma model, and
that the combination is therapeutically superior to either treatment alone.
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Survival Experiment Testing Delta-24-RGDOX Combined with 1MT
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Figure 16: Combined Delta-24-RGDOX and 1MT provides a survival advantage over
either treatment alone and induces anti-glioma memory in a murine immunocompetent
glioma model.
(A) Mice were bolted on day -7, followed by injection of 5x104 GL261-5 cells on day 0. On
day 7, mice were split up into four treatment groups including PBS (control), 1MT, Delta-24RGDOX, or combined 1MT and Delta-24-RGDOX. Mice received Delta-24-RGDOX (5x107
pfu/mouse) on days 7, 9, and 11. 1MT treatment started on day 7 and lasted until day 35.
Panel (B) shows a survival plot of C57BL/6 mice bearing GL261-5 tumors treated with PBS,
1MT, Delta-24-RGDOX, or combined 1MT and Delta-24-RGDOX (n=10). Mice surviving
120 days from the combined Delta-24-RGDOX and 1MT treatment group were re-challenged
with the same cell line on the contralateral hemisphere and observed for survival. Panel (C)
shows a survival plot of combined 1MT and Delta-24-RGDOX treated mice re-challenged
with the same cell line on the contralateral brain hemisphere compared to control naïve mice
(n=5). I.C., intracranial. I.T., intratumoral. OG, oral gavage. BID, bis in die, twice daily.
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Figure 17: Combined Delta-24-RGDOX and Indoximod leads to tumor regression in a
murine immunocompetent glioma model.
Following the same treatment schedule as in Figure 16, mice were sacrificed 15 and 24 days
after tumor implantation, brains were collected in formalin for embedding, sectioning, and
H&E staining. Panel (A) shows representative H&E staining images of GL261-5 bearing
mouse brains treated with PBS, Indoximod, Delta-24-RGDOX, or combined Indoximod and
Delta-24-RGDOX 15- and 24-days post tumor implantation. Panel (B) shows the average
tumor areas in differently treated mice on day 15 of GL261-5 bearing C57BL/6 mouse brains.
Aperio ImageScope software was used to acquire images and to measure areas of high-grade
cellularity (µm2). Column graph values represent mean ± SD (n=5+).
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Figure 18: Combined Delta-24-RGDOX and Indoximod treatment induces tumor
regression in GL261-5 bearing mice.
Following the same treatment schedule as in Figure 16, mice were sacrificed on (A) day 15
or (B) day 24, and brains were collected in 10% buffered formalin and transferred to 70%
ethanol after 24 hours. Brain tumor coronal sections were embedded in paraffin and sectioned
in 5µm slices using a microtome and affixed onto positively charged glass slides. Slides were
subjected to hematoxylin and eosin staining via conventional methods. Slides were scanned
using the Aperio ImageScope-Pathology Slide Viewing Software.
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Figure 19: Combined Delta-24-RGDOX and Indoximod treatment shows a survival
advantage in B16-melanoma brain tumor bearing mice.

Panel (A) shows the treatment schedule, where mice were bolted on day -7, followed by
injection of 1x103 B16 cells on day 0. On day 7, mice were split up into three treatment groups
including PBS (control, n=6), Delta-24-RGDOX (n=7), or combined Delta-24-RGDOX and
Indoximod (n=7). Mice received Delta-24-RGDOX (5x107 pfu/mouse) on days 7, 9, and 11
(when applicable). Indoximod treatment started on day 7 and lasted an additional 28 days
(when applicable). Panel (B) shows a survival plot of the differently treated C57BL/6 mice
bearing B16 brain tumors. I.C., intracranial, I.T., intratumoral. OG, oral gavage. BID, bis in
die, twice daily.
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Figure 20: Combined Delta-24-RGDOX and BGB-7204 treatment results in the smallest
tumor mass compared to single agent treatments in GSC-005 brain tumor bearing mice.
4

Mice were bolted on day -7, implanted with the 5x10 GSC-005 cells on day 0, injected with
7
Delta-24-RGDOX (2.5x10 pfu/mouse in 5µL) or PBS on days 9, and 11, and treated with
100 mg/kg BID per mouse of BGB-7204 on days 7-24. Panel (A) shows representative H&E
staining images of coronal mouse sections on day 24. Panel (B) shows average tumor areas in
differently treated mice on day 24 of these GSC-005 bearing C57BL/6 mouse brains. The
methods described in Figure 17 were used. Column graph values represent mean ± SD
(n=3+).
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Figure 21: Combined BGB-7204 and Delta-24-RGDOX treatment induces tumor
regression in GSC-005 tumor bearing mice.

The figure shows H&E images of mouse brain coronal sections of C57BL/6 GSC-005 bearing
4
mice. Mice were bolted on day -7, implanted with the 5x10 GSC-005 cells on day 0, injected
7
with Delta-24-RGDOX (2.5x10 pfu/mouse in 5µL) or PBS on days 9, and 11, and treated
with 100 mg/kg BID per mouse of BGB-7204 on days 7-24. Mice were sacrificed on day 24,
and brains were collected in 10% buffered formalin and transferred to 70% ethanol after 24
hours. Brain tumor coronal sections were embedded in paraffin and sectioned in 5µm slices
using a microtome and affixed onto positively charged glass slides. Slides were subjected to
hematoxylin and eosin staining via conventional methods. Slides were scanned using the
Aperio ImageScope-Pathology Slide Viewing Software.
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Conclusions
In the current study, we have provided data to support our rationale to combine IDO
inhibitors and Delta-24-RGDOX for the treatment of murine glioma including: 1) Delta-24RGDOX increases IDO expression and activation and 2) the on-target blockade of IDO enhances
the therapeutic efficacy of Delta-24-RGDOX. These data along with previous publications
describing the immunosuppressive mechanisms caused by IDO (24, 27) supported our studies in
determining the efficacy of the combination of IDO inhibitors with Delta-24-RGDOX for the
treatment of murine glioma.
To assess the combination of Delta-24-RGDOX combined with IDO inhibitors, we used
several murine tumor models that were syngeneic to the immunocompetent C57BL/6 mouse,
including murine gliomas, GL261-5 and GSC-005, and murine melanoma, B16. The survival and
histopathology of the tumor-bearing brains of these mice were studied following treatments with
PBS, IDO inhibitor alone, Delta-24-RGDOX alone, or the combination of Delta-24-RGDOX and
IDO inhibitor. The IDO inhibitors used included Trp-mimetics, 1MT and Indoximod, and direct
IDO enzyme inhibitor, BGB-7204. These studies resulted in the following conclusions:
1) Mice bearing intracranial tumors including the immunocompetent GL261-5, GSC-005,
and the B16 (melanoma) models benefit from Delta-24-RGDOX treatment; when IDO
inhibitors are combined with Delta-24-RGDOX, the therapeutic effect increases.
2) The enhanced therapeutic effect of the combination treatment was evident with both Trpmimetics (1MT or Indoximod) and direct IDO enzyme inhibitors (BGB-7204).
3) The enhanced therapeutic effect was indicated by more survival and greater decreases in
the tumor mass in brain tumor bearing mice treated with combined Delta-24-RGDOX and
IDO inhibitor treatment compared to mice treated with Delta-24-RGDOX alone or IDO
inhibitor alone.
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4) The minimal therapeutic effect of treatment by the IDO inhibitor alone indicated that IDO
inhibitors may be effective when combined with another agent.
5) The rejection of a second tumor implantation in mice previously treated with the
combination of Delta-24-RGDOX and IDO inhibitors suggests induction of an antiglioma immune memory response.
6) There were no obvious signs of general toxicity by the mice, including hunched posture,
diarrhea, or weight loss, by the combination treatment.
These results strengthen our rationale to translate this proposed treatment strategy into the clinic.

83

Chapter 8: The therapeutic efficacy of the combination of IDO inhibitor and Delta-24-RGDOX
treatment requires CD4+ helper T Cells.

Rationale and Expectations
Thus far, we can postulate that Delta-24-RGDOX induces both tumor-promoting and antitumor immune responses, as evident by 1) the RNA-sequencing data, 2) the induction of IDO
expression and activation by Delta-24-RGDOX in glioma bearing mice, 3) the greater survival
effect in Delta-24-RGDOX treated mice compared to PBS treated mice bearing gliomas, and 4)
the enhanced therapeutic responses in glioma bearing mice by the combined Delta-24-RGDOX
and IDO inhibitor treatment compared to treatment with Delta-24-RGDOX alone. We can further
speculate that the enhanced therapeutic efficacy of the combination compared to single agent
treatments is due to the generation of an immune memory against glioma antigens as indicated by
our previous survival study that showed 100% survival in re-challenged mice that were previously
treated with the combination therapy.
To further evaluate to which extent the immune component, particularly the role of Thelper cells, is responsible for the anti-cancer effect, we depleted CD4+ T cells in
immunocompetent GL261-5 glioma bearing mice treated with Delta-24-RGDOX or the
combination Delta-24-RGDOX and IDO inhibitor. The depletion of specific CD4+ T cells can be
achieved by serial intraperitoneal injections of CD4 neutralizing antibodies (BioXCellInVivoMAb anti-mouse CD4, clone GK1.5) in mice.
OX40 is a costimulatory receptor that is primarily activated on CD4+ T cells and is heavily
involved in regulation of CD4+ and CD8+ T cell proliferation, differentiation, and survival (92,
93, 176, 177). These OX40 activation mechanisms are supported by our previous studies that
demonstrated a significant survival effect of Delta-24-RGDOX using the immunocompetent
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GL261-5 glioma model; by contrast, when GL261-5 glioma cells were implanted in athymic
immunodeficient mice and treated with Delta-24-RGDOX, 100% of the mice died, indicating the
dependence of Delta-24-RGDOX on the immune system for therapeutic efficacy (91).
Patterns of survival in mice receiving treatment of Delta-24-RGDOX alone or together
with the administration of an IDO inhibitors plus the CD4 neutralizing antibody should provide
mechanistic data about the role of CD4+ T cells on oncolytic virotherapy.
Based on the current literature and our previous findings, we expected the following:
1) Glioma bearing mice treated with Delta-24-RGDOX and the CD4 neutralizing
antibody will have a similar survival pattern to the control treated mice.
2) Glioma bearing mice treated with the combination of Delta-24-RGDOX, the IDO
inhibitor, and the CD4 neutralizing antibody will have a similar survival pattern to the
control treated mice.
3) Glioma bearing mice treated with the combination of Delta-24-RGDOX, the IDO
inhibitor, and a control antibody will survive longer than the groups treated with the
CD4 neutralizing antibody.
4) CD4+ T cell immune responses against the virus and tumor is required for an antitumor
effect in glioma bearing mice treated with Delta-24-RGDOX or combined Delta-24RGDOX and IDO inhibitor treatment.
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Results
To understand the effects of the helper T cell population on the efficacy of combined
Delta-24-RGDOX and IDO inhibitor treatment in murine glioblastoma, we performed a survival
experiment using the GL261-5 C57BL/6 mouse model. The methodology is described in Figure
22A, where mice were bolted 7 days prior to an intracranial 5 x 104 GL261-5 cell injection
followed by three doses of Delta-24-RGDOX (5 x 107 pfu/mouse) on days 7, 9, and 11. Treatment
groups included 1) control (PBS) + IgG, 2) Delta-24-RGDOX + anti-CD4 (for depletion of helper
T cells), 3) Delta-24-RGDOX + Indoximod + anti-CD4, and 4) Delta-24-RGDOX + Indoximod
+ IgG. Figure 23 shows validation of CD4+ T cell depletion.
As expected, the control group had a median survival of 40 days (Figure 22B).
Interestingly, the mice treated with the CD4 depletion antibody and Delta-24-RGDOX or
combined Delta-24-RGDOX and Indoximod had a median survival of 33 or 36 days, respectively,
which mirrored the control group treated with PBS + IgG (PBS + IgG vs Delta-24-RGDOX +
anti-CD4, p = 0.0732; vs. Delta-24-RGDOX + Indoximod + anti-CD4, p = 0.5989). This indicates
the dependency of Delta-24-RGDOX and/or Indoximod on the T helper CD4+ population for the
therapeutic and long-term survival effect. Mice treated Delta-24-RGDOX + Indoximod + IgG had
a 100% survival after 100 days, confirming the therapeutic efficacy of combined Delta-24RGDOX with a Trp-mimetic (Indoximod) in this brain tumor model (Delta-24-RGDOX +
Indoximod + anti-CD4 vs. Delta-24-RGDOX + Indoximod + IgG, p < 0.0001).
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Figure 22: Therapeutic efficacy of combined IDO inhibition and Delta-24-RGDOX
treatment requires CD4+ helper T cells.
Panel (A) shows the treatment schedule, where mice were bolted on day -7, followed by
intracranial injections of 5x104 GL261-5 cells on day 0. On day 7, mice were split up into four
treatment groups including 1) PBS (control) plus IgG control antibody (BioXCellInVivoMAb rat IgG2b isotype control, anti-keyhole limpet hemocyanin), 2) Delta-24RGDOX plus CD4 neutralizing antibody (BioXCell-InVivoMAb anti-mouse CD4 (clone
GK1.5)), 3) Delta-24-RGDOX and Indoximod plus CD4 neutralizing antibody, and 4) Delta24-RGDOX and Indoximod plus IgG control antibody. Mice received Delta-24-RGDOX
(5x107 pfu/mouse) on days 7, 9, and 11. Indoximod treatment started on day 7 and lasted an
additional 28 days. Neutralizing or control antibodies were administered, intraperitoneally,
every fourth day for nine rounds. Panel (B) shows the survival of differently treated mice.
I.C., intracranial. I.T., intratumoral. OG, oral gavage. BID, bis in die, twice daily.
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Figure 23: CD4 neutralizing antibodies deplete CD4 populations in vivo.
This figure supplements the survival study of GL261-5 bearing mice treated with Delta-24RGDOX and/or Indoximod with or without CD4 depletion antibodies, seen in Figure 22. Mice
were treated with CD4 neutralizing antibodies (αCD4: BioXCell-InVivoMAb anti-mouse
CD4 (clone GK1.5)) or an unreactive IgG (IgG2b: BioXCell-InVivoMAb rat IgG2b isotype
control, anti-keyhole limpet hemocyanin) to serve as a control. On day 38 post-tumor implant,
one mouse from each treatment was sacrificed. Spleens were collected and processed into
single cells and stained for CD3, CD4, and CD8, then analyzed using flow cytometry. Flow
cytometry plots show CD4 and CD8 populations of the (A) naïve, (B) IgG2b, or (C) anti-CD4
treated mice. D) The column graph shows the frequency of the CD4 population in the indicated
treatment group.
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Conclusions
Our previous studies underscore the importance of the host immune system to elicit the
antitumor effects of Delta-24-RGDOX in glioma bearing mice (91). To further study the role of
CD4+ T helper cells during Delta-24-RGDOX or combined Delta-24-RGDOX and IDO inhibitor
treatment, we conducted a survival study of glioma bearing mice with these respective treatments
with or without depletion of the CD4+ T helper cell population.
Our results indicate that we successfully depleted the CD4+ T cell population allowing us
to accurately determine the role of CD4+ T helper cells on the therapeutic efficacy of Delta-24RGDOX or combined Delta-24-RGDOX and Indoximod treatment in an immunocompetent
murine glioma model. As such, we can make the following conclusions:
1) The therapeutic efficacy and antitumor effect of Delta-24-RGDOX or combined Delta24-RGDOX and IDO inhibitor treatment requires CD4+ T cell activity of the host.
2) The superior survival effects of combined Delta-24-RGDOX with Trp-mimetic,
Indoximod in the GL261-5 glioma model is reproducible.
The 100% death of glioma bearing mice caused by the depletion of the CD4+ T helper
population is congruent with the outcomes of the enhanced OX40 receptor pathway activation
elicited by Delta-24-RGDOX. More specifically, the OX40 receptor is a T cell activator with
major effects on CD4+ T cells (144, 177).
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Chapter 9: The combination of Delta-24-RGDOX and IDO inhibitors increases the amount of
intratumoral T cells and decreases the count of immune tolerant populations.

Rationale and Expectations
The IDO pathway metabolite, Kyn, activates AhR in several populations of immunerelated cells, shaping the pro-tumorigenic functions of the tumor microenvironment (27, 42, 164,
165). Depletion of Trp, and the subsequent excess of Kyn in the tumor microenvironment results
in suppression of T-cell function and induction of T-cell apoptosis (35). Kyn-mediated activation
of AhR promotes FOXP3+ regulatory T cell differentiation (32, 33). In addition, the IDO-KynAhR cascade has been linked to Th17 differentiation (178, 179) of T helper cells, whose
suppressive function has been associated with tumor immunosuppression (180). The activation of
the IDO pathway also elicits integrated stress responses via Trp depletion leading to IL-6 cytokine
signaling, which is essential for MDSC formation (36, 37).
The IDO-Kyn-AhR molecular cascade may further influence the tumor microenvironment
in the context of virotherapy because it is involved in the host immune response against viruses.
In agreement with this data, the IDO-Kyn-AhR pathway is an important environmental modulator
that contributes to the prevalence and severity of viral infections (181). Therefore, we were
interested in ascertaining the extent to which the infection of gliomas by Delta-24-RGDOX
prompts activation of the IDO-Kyn-AhR pathway in the tumor microenvironment. In fact, we
were able to show the increased induction of IDO expression and activation in vivo in Delta-24RGDOX treated brain tumors compared to PBS-treated, seen in Figures 9 and 10.
The IDO-Kyn-AhR activation after oncolytic virus administration may further contribute
to increased tumor immunosuppression and, in turn, facilitate the glioma’s ability to evade the Tcell immune response elicited by virotherapy. In agreement with this, we observed an enhanced
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therapeutic efficacy of combined Delta-24-RGDOX and IDO inhibitor treatment compared to
Delta-24-RGDOX treatment alone in murine glioma, as discussed in Chapters 7 and 8.
Consequently, we expected that adding an IDO inhibitor to Delta-24-RGDOX would increase
general T cell populations (CD3+, CD4+, and CD8+ T cells) and decrease immunosuppressive
populations, such as Tregs or MDSCs, within the tumor microenvironment. More specifically, we
expected the following:
1) Delta-24-RGDOX treatment will increase the immunogenicity of murine gliomas.
Particularly, Delta-24-RGDOX will increase both anti-tumor and pro-tumorigenic
immune populations, including CD4+ T helper cells, cytotoxic CD8+ T cells,
regulatory T cells, and myeloid derived suppressor cells.
2) IDO inhibitors will enhance the infiltration of CD4+ T helper cells and cytotoxic CD8+
T cells generated by Delta-24-RGDOX in murine glioma.
3) IDO inhibitors will decrease the infiltration of immune tolerant populations (Tregs and
MDSCs) generated by Delta-24-RGDOX in glioma.

91

Results
The combination of Delta-24-RGDOX with IDO inhibitors increases the frequency of
intratumoral T cells.
To further understand the mechanism underlying the anti-cancer effect of the combination
of Delta-24-RGDOX and IDO inhibitors, we examined phenotypic changes of lymphocyte
populations within the tumor from the GL261-5 or GSC-005 bearing mice treated with 1) PBS,
2) IDO inhibitor alone, 3) Delta-24-RGDOX alone, or 4) combined IDO inhibitor and Delta-24RGDOX. After treating the mice with indicated treatment for 17 days, we isolated braininfiltrating lymphocytes and stained them to identify tumor-infiltrating CD3+ cells, T-helper CD4+
cells, and cytotoxic CD8+ T lymphocytes by flow cytometry. As expected, Delta-24-RGDOX
treatment resulted in an increase in tumor-infiltrating CD3+, T-helper CD4+ cells, and cytotoxic
CD8+ T lymphocytes per hemisphere after 17 days of treatment (Figures 24A and 27) compared
to PBS or IDO inhibitor treated mice in both the GL261-5 and GSC-005 model. Of interest, the
combination of Delta-24-RGDOX and IDO inhibitor treatment led to highest absolute count per
hemisphere in the CD3+, CD4+, and CD8+ populations compared to all other groups (Figures 24A
and 27; p < 0.05, all populations). This pattern was also confirmed in CD3+
immunohistochemistry, where the highest amounts of CD3+ staining density occur in mouse
tumors treated with combined Delta-24-RGDOX and IDO inhibitor treatment (Figure 24B).
Representative images of the CD3+ IHC for both models of individual mice are seen in Figures
25 and 26.
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The combination of Delta-24-RGDOX with IDO inhibitors decreases the frequency of immune
tolerant populations.
Furthermore, to determine the tolerant immune effects within the tumor microenvironment
produced by the combination of Delta-24-RGDOX and Indoximod, we used flow cytometry to
analyze the populations of regulatory T cells (CD4+, FOXP3+, CD25+) and myeloid-derived
suppressor cells (CD45+, GR1+, CD11b+) of GL261-5 brain tumors after 17 days of treatment or
24 days after the tumor implant. RNA sequencing analyses revealed that GL261-5 tumors treated
with Delta-24-RGDOX harbored enrichment of Treg and MDSC gene sets (Figure 28A and 28C).
This result was validated by the flow cytometry assays, which showed that the mice treated with
Delta-24-RGDOX alone had more Tregs and MDSCs per hemisphere than PBS-treated or
Indoximod-treated mice had (Figure 28B and 28D). Notably, the mice treated with the
combination of Delta-24-RGDOX and Indoximod had fewer Tregs and MDSCs than the mice
treated with Delta-24-RGDOX only had (p < 0.0001, both populations). These data indicate the
decrease in immune-tolerant populations when Delta-24-RGDOX was combined with IDO
inhibitors.
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Figure 24: The combination of Delta-24-RGDOX with IDO inhibitors increases the
absolute count per hemisphere of intratumoral T cells in murine glioma.
Mice were bolted on day -7, then implanted with 5 x 104 GSC-005 or GL261-5 cells on day
0; on days 9 and 11 (GSC-005) or days 7, 9, and 11 (GL261-5), the mice were intracranially
injected with PBS, Delta-24-RGDOX (2.5 x 107 (GSC-005) or 5 x 107 (GL261-5) pfu/dose).
IDO inhibitors (IDOi: Indoximod, 275 mg/kg or BGB-7204, 100 mg/kg, BID) were
administered from days 7 to 24. On day 7, mice were split up into four treatment groups
including PBS (control), IDOi, Delta-24-RGDOX, or combined IDOi and Delta-24-RGDOX.
We sacrificed the mice on day 24. The brain tumor bearing mouse brains were collected and
processed into single cells and enriched for immune cells using a percoll gradient. Immune
cells were stained for CD3, then analyzed using flow cytometry. Panel (A) shows column
graphs of absolute count of cells/hemisphere for the CD3+ T cell population. Panel (B) shows
representative images of brain tumor sections of the differently treated mice stained for CD3
by immunohistochemistry. Images were acquired using the Aperio ImageScope-Pathology
Slide Viewing Software.
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Figure 25: BGB-7204 enhances CD3+ T cell infiltration of Delta-24-RGDOX infected
GSC-005 brain tumors.
Representative images of CD3 immunohistochemistry of individual mice in the different
treatment groups of GSC-005 brain tumor bearing mice. Mice were bolted on day -7,
implanted with the 5x104 GSC-005 cells on day 0, injected with Delta-24-RGDOX (2.5x107
pfu/mouse in 5µL) or PBS on days 9 and 11, and/or treated with 100 mg/kg per mouse of
BGB-7204 on days 7-24. Mice were sacrificed on day 24, and brains were collected and fixed
in 10% buffered formalin and transferred to 70% ethanol after 24 hours. Brain tumor coronal
sections were embedded in paraffin and sectioned in 5µm slices onto positively charged glass
microscope slides using a microtome. Slides were stained for anti-CD3 using
immunohistochemistry. Slides were scanned and images were acquired using the Aperio
ImageScope-Pathology Slide Viewing Software.
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Figure 26: Indoximod enhances CD3+ T cell infiltration of Delta-24-RGDOX infected
GL261-5 brain tumors.
Representative images of CD3 immunohistochemistry of individual mice in the different
treatment groups of GL261-5 brain tumor bearing mice. Mice were bolted on day -7,
4
7
implanted with the 5x10 GL261-5 cells on day 0, injected with Delta-24-RGDOX (5x10
pfu/mouse in 5µL) or PBS on days 7, 9, and 11, and/or treated with 275 mg/kg per mouse of
Indoximod on days 7-24. Mice were sacrificed on day 24, and brains were collected and fixed
in 10% buffered formalin and transferred to 70% ethanol after 24 hours. Brain tumor coronal
sections were embedded in paraffin and sectioned in 5µm slices onto positively charged glass
microscope slides using a microtome. Slides were stained for anti-CD3 using
immunohistochemistry. Slides were scanned and images were acquired using the Aperio
ImageScope-Pathology Slide Viewing Software.
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Figure 27: IDO inhibitors increase the frequency of intratumoral CD4+ and CD8+ T cell
populations generated by Delta-24-RGDOX infection in murine gliomas.
Following the same treatment scheme as in Figure 24, the mouse brain tumors were collected
and processed into single cells and enriched for immune cells using a percoll gradient.
Immune cells were stained for CD45, CD3, CD4, and CD8, then analyzed using flow
cytometry. Column graphs show absolute count of cells per hemisphere for the (A/B) CD4+
and (C/D) CD8+ populations within the brain tumor microenvironment of the differently
treated mice of the (A/C) GSC-005 or (B/D) GL261-5 murine glioma model.
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Figure 28: Delta-24-RGDOX induces regulatory T cells and myeloid derived suppressor
cells within the glioma microenvironment, which can be suppressed with the addition of
an IDO inhibitor.
Mice were bolted on day -7, implanted with the 5x104 GL261-5 cells on day 0, injected with
Delta-24-RGDOX (5x107 pfu/mouse in 5µL) or PBS on days 7, 9, and 11, and/or treated with
275 mg/kg per mouse of Indoximod on days 7-24. On day 12, RNA from the brain tumors
were submitted to gene sequencing enrichment analysis to determine enrichment of the (A)
Treg or (C) MDSC gene sets in PBS or Delta-24-RGDOX treated brain tumors. Mice were
sacrificed on day 24, and brains were processed into single cells and enriched for immune
cells using a percoll gradient. Immune cells were stained for CD45, CD3, CD4, CD8, CD25,
FOXP3, CD11b, and GR1, then analyzed by flow cytometry. Column graphs show absolute
count of cells per hemisphere of tumor tolerant populations, B) regulatory T cells or D)
myeloid derived suppressor cells.
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Conclusions
We developed the next generation of Delta-24-RGD by adding the OX40L to the
backbone of the virus to enhance the immune responses via co-stimulation of the OX40 receptor
of activated T cells. Our previously published studies show that treatment of murine glioma with
Delta-24-RGDOX increases both immune-activating and immune-suppressing properties within
the tumor microenvironment, including more infiltration of CD8+ T cells or higher expression of
PD-L1 on glioma cells compared to PBS or Delta-24-RGD treatment (91). In the current study,
we also showed that Delta-24-RGDOX can contribute to immunosuppressive properties, as
indicated by elicitation of IDO or AhR expression and activation (Chapter 4). The enhanced
survival of glioma bearing mice treated with combined Delta-24-RGDOX and IDO inhibitor
treatment compared to Delta-24-RGDOX alone, as discussed in Chapter 7, also suggests a level
of immunosuppression generated by Delta-24-RGDOX that allows immune evasion of antitumor
responses.
To determine how the combination treatment of Delta-24-RGDOX and IDO inhibitors
remodels the immune landscape of the glioma microenvironment, we studied the infiltration of
different immune populations, including CD4+ T cells, CD8+ T cells, Tregs, and MDSCs, in brain
tumors of mice treated with PBS, IDO inhibitor alone, Delta-24-RGDOX alone, or combined
Delta-24-RGDOX and IDO inhibitor. Based on these studies, we can make the following
conclusions:
1) The infiltration of CD3+, CD4+, and CD8+ T cells by Delta-24-RGDOX can be
enhanced with IDO inhibitors in two immunocompetent murine glioma models, GSC005 and GL261-5. Furthermore, we were able to show this phenomenon using both
Trp-mimetics (Indoximod) and direct IDO enzyme inhibitors (BGB-7204).
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2) The use of IDO inhibitors alone provides minimal immunological responses, which
corresponds to its similar survival pattern of PBS-treated mice.
3) In all cell populations studied, including that of CD3+ T cells, CD4+ T cells, CD8+ T
cells, Treg, or MDSCs, there was minimal and similar absolute count/hemisphere in
the PBS- and IDO inhibitor-treated mice.
4) Delta-24-RGDOX treatment increased the absolute count per hemisphere of CD3+ T
cells, CD4+ T cells, CD8+ T cells, Treg, or MDSCs, indicating the transformation of
these non-immunogenic murine brain tumors into more immunogenic tumors.
5) The combined Delta-24-RGDOX and IDO inhibitor treatment decreased the absolute
count/hemisphere of the immunosuppressive Treg and MDSC populations in
comparison to Delt-24-RGDOX single treatment.
Overall, our studies indicates that Delta-24-RGDOX enhances infiltration of both
immune-activating and immune-suppressive populations; in comparison, the addition of IDO
inhibition to Delta-24-RGDOX increases the immune activating populations and decreases the
immune suppressive populations. This reshaping of the tumor microenvironment should favor
the identification and destruction of the infected tumor by the immune system of the host.
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Chapter 10: The combination of IDO inhibitors and Delta-24-RGDOX increases T-cell
activation against tumor and viral antigen, which is negatively regulated by kynurenine.

Rationale and Expectations
Our pre-clinical studies have shown that in comparison to Delta-24-RGD, Delta-24RGDOX enhances the survival of glioma mice, which was accompanied by an increase in
functional T cell responses by both brain infiltrating lymphocytes and splenocytes (91). Still, as
discussed in this dissertation, Delta-24-RGDOX can also produce immunosuppression, as
supported by 1) the elicitation of IDO activation in both the GL261-5 and GSC-005 murine glioma
models and 2) the increased infiltration of immunosuppressive immune populations, Tregs and
MDSCs.
The activation of the IDO-Kyn-AhR pathway (Figure 29A) results in apoptosis and
anergy of T effector cells and activation of Tregs (27, 29). The amalgamation of these
observations and our results obtained from our current studies led us to our hypothesis that
combined Delta-24-RGDOX and IDO inhibitor treatment would increase T cell functions against
viral and tumor antigens compared to the single agent treatments. Thus, to confirm our hypothesis
we conducted ex vivo/in vivo co-culture experiments, where target parental cancer cells (mock
infected or Delta-24-RGDOX infected) were cultured with splenocytes from the differently
treated glioblastoma-bearing treated mice. Using the supernatants from these co-cultures, we
performed ELISAs to detect levels of different T-cell activation cytokines, including IFNγ and
IL-2. To determine T-cell function in the context of IDO activation, we also tested the secretion
of IFNγ and IL-2 of these co-cultures in the presence of Kyn. Additionally, we used cells that
overexpress IDO in some cases to determine the effect of constitutive IDO overexpression on Tcell function.
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Based on our previous studies and supporting data, we expected the following:
1) Compared to splenocytes from PBS treated glioma bearing mice, splenocytes from
Delta-24-RGDOX treated mice will yield higher levels of IFNγ and IL-2 when cocultured with mock or virally infected target cells.
2) The levels of IFNγ and IL-2 will be even higher in co-cultures of splenocytes from
mice treated with combined Delta-24-RGDOX and IDO inhibitor treatment.
3) The levels of IFNγ and IL-2 will decrease in cultures that contained Kyn or targets that
constitutively overexpress IDO.
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Results
Combined IDO inhibition and Delta-24-RGDOX increases T-cell activation against tumor and
viral antigen.
To study the functional modifications of T cells in response to treatment, the activity of
the systemic lymphocyte population was assessed by detecting the secretion of the Th1 cytokines,
IFN and IL-2, by splenocytes from GL261-5-bearing mice treated with PBS, Delta-24-RGDOX,
Indoximod, or combined Delta-24-RGDOX and Indoximod stimulated with tumor and/or viral
antigens. Specifically, as outlined in Figure 29B, C57BL/6 mice were implanted with 5 × 104
GL261-5 cells and underwent indicated treatment at specified times; mice were then sacrificed on
day 24 to permit analysis of T-cell function. The splenocytes from these differently treated mice
were cultured in the presence of different groups of target cells including mock infected GL2615 cells or Delta-24-RGDOX-infected GL261-5 cells. It was noteworthy that among splenocytes
cultured with mock-infected GL261-5 cells, secretion of IFNγ and IL-2 was enhanced in
splenocytes derived from mice previously infected with Delta-24-RGDOX compared to mice
previously treated with PBS or Indoximod alone (p < 0.05, both groups), as seen in Figure 29C.
Activation, via IFNγ and IL-2 secretion, is further enhanced against the tumor antigens (Mock
GL261-5 Target Cells) in splenocytes from mice previously treated with the combination of
Delta-24-RGDOX and Indoximod compared to Delta-24-RGDOX alone (Figure 29C, IFNγ, p =
0.0157; IL-2 p = 0.0333). Similarly, the highest amount of secretion of IFNγ and IL-2 against the
Delta-24-RGDOX infected target cells comes from the splenocytes from mice were treated with
combined Delta-24-RGDOX and Indoximod (Figure 29D). These results suggested that
splenocytes not only are activated against viral antigens but also recognize tumor antigens.
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We performed a similar experiment as described above to study the T-cell function at 15
days in the same GL261-5 model to study this effect over time. In splenocytes cultured with mockinfected GL261-5 target cells, the trends in IFNγ secretion on day 15 were similar to those on day
24 (Figure 30B), where we saw highest amount of IFNγ secretion in splenocytes that came from
combination-treated mice when cultured with mock infected GL261-5 cells. Interestingly, as seen
in Figure 30C, when the splenocytes were cultured with Delta-24-RGDOX infected GL261-5
cells, levels of IFNγ secretion were higher on day 15 than on day 24 by nearly 10-fold in the
splenocytes from Delta-24-RGDOX-treated or combination-treated mice. Moreover, on day 15,
the levels of IFNγ secretion were similar in splenocytes from Delta-24-RGDOX-treated and
combination-treated mice; notably, the secretion values in these splenocytes were about 50 times
as high as the values in splenocytes from control and Indoximod-treated mice. This could indicate
an early robust anti-viral immune effect and perhaps the conversion to a relatively less immuneactivating environment generated by clearance of the virus and complete tumor eradication by
day 24. Overall, these functional studies showed that lymphocytes from the combination treated
mice recognized not only viral antigens but also tumoral antigens, suggesting the triggering of
anti-tumoral immunity.
We next performed experiments using the GSC-005 C57BL/6 murine glioma model. As
outlined in Figure 31B, C57BL/6 mice were implanted with 5 × 104 GSC-005 cells and underwent
indicated treatment at specified times; mice were then sacrificed on day 24 to permit analysis of
T-cell function. As seen in Figure 31, on day 24, splenocytes from the combination-treated mice
secreted highest levels of IFNγ compared to splenocytes from all other groups when stimulated
GSC-005 cells that were treated with a mock infection (Figure 31C, p = 0.0003) or treated with
BGB-7204 and infected with Delta-24-RGDOX (Figure 31E, p = 0.0003). These data
complement the data seen with the GL261-5 model and suggests the enhanced T-cell function in
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splenocytes of mice that were treated with combined IDO inhibitor and Delta-24-RGDOX
treatment compared to either treatment alone.

Kyn or constitutive IDO expression negatively regulates T-cell activation against tumor and viral
antigen.
Because kynurenine has been reported to be involved with immunosuppression, we then
wanted to dissect the role of kynurenine on T-cell activation using this same assay. To test this
theory, we performed similar functional co-culture assays with kynurenine added to the cultures.
Specifically, in a separate animal experiment, C57BL/6 mice were bolted on day -7, implanted
with 5x104 GSC-005 cells on day 0, and split into two groups that included PBS or Delta-24RGDOX (1x108 pfu/mouse on days 7, 10, and 13). On day 15, mice were sacrificed, and
splenocytes were then stimulated with pre-fixed uninfected (Mock) (Figure 32A/B left) or Delta24-RGD infected (Figure 32A/B right) GL261 (Figure 32A) or GL261-IDO-OE cells (Figure
32B); an additional group that also contained kynurenine within the media was added. As
expected, as seen in Figure 32A, the secretion of IL-2 was increased in splenocytes that came
from Delta-24-RGD infected mice compared to PBS treated mice when cultured with either the
mock infected or Delta-24-RGD infected GL261 cells (p=0.0039, p=0.0490, respectively),
indicating the T cell activation against both tumor and viral antigen generated by Delta-24-RGD.
Interestingly, when kynurenine was added to the cultures containing Delta-24-RGD treated
splenocytes, the secretion of IL-2 was significantly reduced, suggesting the anti-tumor effect
generated by kynurenine (mock GL261 target, p=0.0381; Delta-24-RGD infected GL261 target,
p=0.0446). When these same experiments were done using the GL261-IDO-OE target cells, as
seen in Figure 32B, the secretion of IL-2 of splenocytes from Delta-24-RGD infected mice when
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cultured with the mock GL261-IDO-OE or Delta-24-RGD infected GL261-IDO-OE was either
unchanged or diminished, respectively, compared to splenocytes from PBS treated mice.
Furthermore, the IL-2 secretion of co-cultures containing either mock infected GL261-IDO-OE
or Delta-24-RGD infected GL261-IDO-OE target cells with Delta-24-RGD treated splenocytes
were significantly decreased when kynurenine was added to the cultures (mock target, p = 0.0355,
Delta-24-RGD target, p = 0.0271), reinforcing the claim that the anti-tumor immune effect can be
generated by kynurenine. Of note, the magnitude of IL-2 levels is decreased in the co-cultures
that involved GL261-IDO-OE compared to WT GL261 co-cultures, suggesting the negative
regulation of T-cell activation by constitutive IDO overexpression. Overall, these experiments
elucidate the complex relationship between IDO, Kyn, and viral infection on the immune response
against tumor and viral antigens in these murine glioma models.
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Figure 29: Indoximod combined with Delta-24-RGDOX treatment increases T-cell
activation against glioma and viral antigen.

Panel (A) shows a schematic of the IDO-Kyn-AhR circuit. Panel (B) shows the schematic of
4
experimental timeline, where mice were bolted on day -7, implanted with the 5x10 GL2617
5 cells on day 0, injected with Delta-24-RGDOX (5x10 pfu/mouse in 5µL) or PBS on days
7, 9, and 11, and/or treated with 275 mg/kg per mouse of Indoximod on days 7-24. Mice were
sacrificed on day 24, and splenocytes were isolated from these GL261-5 bearing mice that
were treated with PBS, Indoximod, Delta-24-RGDOX, or combined Indoximod and Delta24-RGDOX and stimulated with prefixed GL261-5 cells that were (C) uninfected (mock
infection) or (D) infected with Delta-24-RGDOX. Forty-eight hours later, the concentration
of IFNγ (C/D left) or IL-2 (C/D right) in the co-culture supernatant was assessed by ELISA.
Column graphs show mean pg/mL (n=3). I.C., intracranial. I.T., intratumoral. OG, oral
gavage. BID, bis in die, twice daily.
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Figure 30: Indoximod combined with Delta-24-RGDOX treatment increases T-cell
activation against glioma antigen at an early timepoint.
4

Mice were bolted on day -7, implanted with the 5x10 GL261-5 cells on day 0, injected with
7
Delta-24-RGDOX (5x10 pfu/mouse in 5µL) or PBS on days 7, 9, and 11, and/or treated with
275 mg/kg per mouse of Indoximod on days 7-24. Mice were sacrificed on day 15, and
splenocytes were isolated from these GL261-5 bearing mice treated with PBS, Indoximod,
Delta-24-RGDOX, or combined Indoximod and Delta-24-RGDOX and stimulated with
prefixed GL261-5 cells that were (B) uninfected (mock infection) or (C) infected with Delta24-RGDOX. Forty-eight hours later, the concentration of IFNγ in the co-culture supernatant
was assessed by ELISA. Column graphs show mean pg/mL IFNγ (n=3). I.C., intracranial.
I.T., intratumoral. OG, oral gavage. BID, bis in die, twice daily.
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Figure 31: BGB-7204 combined with Delta-24-RGDOX increases T-cell activation
against glioma and viral antigen.
Panel (A) shows a schematic of the IDO-Kyn-AhR circuit. Panel (B) shows the schematic of
experimental timeline, where mice were bolted on day -7, followed by injection of 5x104
GSC-005 cells on day 0. On day 7, mice were split up into three treatment groups including
BGB-7204 alone, Delta-24-RGDOX alone, or combined BGB-7204 and Delta-24-RGDOX.
Mice received Delta-24-RGDOX (2.5x107 pfu/mouse) on days 9 and 11. BGB-7204
treatment started on day 7 at a dose of 100 mg/kg twice daily and lasted until day 24, when
we sacrificed the mice. Splenocytes from the differently treated mice were stimulated with
pre-fixed GSC-005 cells that were (C) mock infected, (D) infected with Delta-24-RGDOX,
or (E) treated with BGB-7204 and infected with Delta-24-RGDOX. Forty-eight hours later,
the concentration of IFNγ in the co-culture supernatant was assessed by ELISA (R&D
Systems). The column graphs show of mean pg/mL of IFNγ (n=3). I.C., intracranial. I.T.,
intratumoral. OG, oral gavage. BID, bis in die, twice daily.
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Figure 32: Kyn or constitutive IDO expression negatively regulates T-cell activation
against glioma and viral antigen.
C57BL/6 mice were bolted on day -7, implanted with 5x104 GSC-005 cells on day 0, and
split into two groups that included PBS or Delta-24-RGDOX (1x108 pfu/mouse on days 7,
10, and 13). On day 15, mice were sacrificed, and splenocytes were then stimulated with prefixed (A and B left) uninfected (Mock) or (A and B right) Delta-24-RGDOX infected A)
GL261 or B) GL261-IDO-OE cells; an additional group that also contained 25 µM
kynurenine was added. Forty-eight hours later, the concentration of IL-2 in the co-culture
supernatant was assessed by ELISA (R&D Systems). All column graphs show mean pg/mL
of IL-2 (n=3).
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Conclusions
The results of this dissertation thus far have strengthened our rationale to combine IDO
inhibitors with Delta-24-RGDOX for the treatment of murine glioma. We have demonstrated that
Delta-24-RGDOX induces IDO expression and activation and increases T cell infiltration within
the glioma, which associated with a substantial survival effect in glioma bearing mice. The
addition of an IDO inhibitor to Delta-24-RGDOX further enhances T cell infiltration, decreases
immune tolerant populations, and provides even greater survival benefit in glioma bearing mice.
To further strengthen the rationale of our proposed therapy, we performed functional
studies to determine how combined IDO inhibitor and Delta-24-RGDOX treatment in glioma
bearing mice modulates T cell activation against both viral and glioma antigens. We further
determined the effects of Kyn and constitutive IDO expression on the function of these T cells.
Based off these studies, we can make the following conclusions:
1) Increased T cell function against tumor and viral antigens, via elevated IFNγ and IL2 levels, from splenocytes of Delta-24-RGDOX treated glioma bearing mice was
reproducible (91).
2) T cell function against both viral and tumor antigens was enhanced in splenocytes from
mice treated with combined Delta-24-RGDOX and IDO inhibitor treatment.
3) The presence of Kyn and/or constitutive IDO expression diminished the oncolytic
virus-induced T-cell function recognize viral and glioma antigen.
Overall, these functional studies combined with results describes in this dissertation
strongly validate the central hypothesis of this study, which stated that therapy of Delta-24RGDOX combined with an IDO inhibitor will stimulate a cytotoxic immune response and inhibit
the suppressive immune response against the tumor cells providing a potential effective novel
treatment for glioblastoma.
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Chapter 11: List of Conclusions

1. Delta-24-RGDOX reshapes the murine brain tumor microenvironment.
2. Delta-24-RGDOX increases the predicted diversity and percentage of immune
populations.
3. Delta-24-RGDOX increases both immune-activating and immune-suppressing pathways.
4. Delta-24-RGDOX induces expression of genes from the IDO pathway.
5. IFNγ induces IDO expression in human glioma, murine glioma, and other cancer cells.
6. Delta-24-RGDOX activates the AhR pathway in human cancer cells.
7. Delta-24-RGDOX induces Ahr expression and translocation into the nucleus in human
cancer cells.
8. Delta-24-RGD or Delta-24-RGDOX induces IDO expression in vitro in murine
glioblastoma models.
9. Delta-24-RGD or Delta-24-RGDOX induces IDO expression and activation in vivo of
murine models of cancer.
10. Inhibition of IDO in vitro, does not alter viral infection, viral replication, or viral-induced
cytopathic ability of Delta-24-RGDOX.
11. There is a greater therapeutic effect of Delta-24-RGDOX compared to PBS in IDO-KO
mice bearing glioma.
12. Glioblastoma-bearing IDO-KO mice live longer than WT mice when treated with Delta24-RGDOX.
13. Delta-24-RGDOX combined with Trp-Mimetic, 1MT or Indoximod, leads to a more
robust decrease in tumor mass, provides a survival advantage, and induces anti-tumor
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immunity compared to single agents in the treatment of murine brain tumors compared to
Delta-24-RGDOX treatment alone.
14. Delta-24-RGDOX combined with direct IDO enzyme inhibitor, BGB-7204, results in
greater reduction of tumor size compared to single agents in murine glioblastoma
compared to Delta-24-RGDOX treatment alone.
15. The therapeutic efficacy of Delta-24-RGDOX or combined Delta-24-RGDOX and IDO
inhibitor treatment in murine glioblastoma requires CD4+ T cell activity.
16. Delta-24-RGDOX increases the immunogenicity of murine glioblastoma indicated by
enhanced infiltration of both immune-activating and immune-suppressive populations.
17. The combination of Delta-24-RGDOX with IDO inhibitors increases the frequency of
intratumoral T cells in murine glioblastoma compared to Delta-24-RGDOX treatment
alone.
18. The combination of Delta-24-RGDOX with IDO inhibitors decreases the frequency of
immune tolerant populations, including Tregs and MDSCs, within the murine
glioblastoma microenvironment compared to Delta-24-RGDOX treatment alone.
19. The use of IDO inhibitors alone in the treatment of murine glioblastoma provides minimal
immunological responses and is associated with poor survival.
20. Combined IDO inhibition and Delta-24-RGDOX increases T-cell activation against tumor
and viral antigen in the setting of murine glioblastoma.
21. Kyn or constitutive IDO expression negatively regulates T-cell activation against tumor
and viral antigen in the setting of murine glioblastoma.
22. The use of IDO inhibitors with armed oncolytic adenoviruses provides a potential and
effective treatment for glioblastoma.
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Chapter 12: Discussion
Encouraging results from a phase III clinical trial led to the recent US Food and Drug
Administration approval of the modified type 1 herpes simplex virus, Talimogene laherparepvec
(T-VEC), for treatment of advanced melanoma (182) leading to a resurgence of interest in
oncolytic viruses as a cancer therapy. There is particular interest of oncolytic adenoviruses in the
treatment of glioma because of the convenience of administering the virus intratumorally during
surgery. Currently, eight different families of viruses are being tested for the treatment of glioma.
Overall, these studies have shown us that the treatment of oncolytic viruses results in minimal
toxicity, increases immunogenicity, and can lead to long term survival in 6-25% of patients with
recurrent glioma (90, 97-106, 108, 109, 122, 183). Of these studies, the predecessor of Delta-24RGDOX, Delta-24-RGD, resulted in 20% of patients surviving past three years. Exploratory
objectives of this study showed anti-tumor responses via the elicitation of an immune response,
as indicated by infiltration of T-bet+ CD8+ T cells and the pseudoprogression of a tumor post
treatment before complete regression; this could imply initial generation of inflammation by the
virus before the subsequent anti-tumor immune response (90). These observations support the
emerging paradigm that oncolytic viruses are a type of immunotherapy. These clinical studies
also reveal that single agent therapy of oncolytic viruses will most likely not result in maximal
therapeutic benefits. Hence, we decided to combine Dellta-24-RGDOX with IDO inhibitors for
the treatment of glioblastoma based on observations that 1) IDO is commonly upregulated after
viral infection (58, 66, 166, 170, 184, 185) and 2) IDO causes immunosuppression conducive to
tumor growth (28, 32, 186-188).
Our previous studies show that Delta-24-RGDOX elicits a more potent anti-tumor
immune and immune memory response compared to Delta-24-RGD, leading to more survival of
glioma bearing mice (91). The enhanced immune effect, as evidenced by increased infiltration,
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activation, and memory of lymphocytes within the tumor microenvironment is provided by
activation of the OX40 pathway of the effector T cell via Delta-24-RGDOX induced OX40L
expression on cancer cells (91). These data supported the start of a phase I clinical trial testing
Delta-24-RGDOX on patients with recurrent glioblastoma in Spain (NCT03714334). Despite
these directed anti-tumor immune responses by Delta-24-RGDOX, maximal therapeutic benefits
were never achieved, signifying the presence of a sustained negative regulation of immune
activation against the tumor. Interestingly, the RNA sequencing results revealed that in the
GL261-5 murine glioblastoma model, Delta-24-RGDOX reshaped the tumor microenvironment
producing the upregulation of genes involved in both immune activating and immune suppressive
pathways. Of significance, Delta-24-RGDOX treated brain tumors showed enrichment of the IDO
pathway and its related cell targets, Tregs and MDSCs. Furthermore, the RNA sequencing
analyses revealed elicitation of common immune checkpoint proteins including CTLA-4 and PD1. This result validated our previous studies showed that the combination of Delta-24-RGDOX
and anti-PD-L1 provided a greater survival benefit compared to Delta-24-RGDOX alone in the
GL261-5 murine glioblastoma model (91). Collectively, these data support the ongoing clinical
trial testing the treatment of patients of recurrent glioblastoma with Delta-24-RGD and
pembrolizumab (anti-PD-1) (NCT02798406). The RNA sequencing analyses also validated our
quantitative PCR studies that showed this phenomenon of negative immune regulation elicited by
Delta-24-RGDOX infection, where IDO expression increased in the GL261-5 murine
glioblastoma model and the unrelated 4T1.2 murine breast cancer model in response to the viral
infection.
Activation of IDO by Delta-24-RGDOX was also evident in the GL261-5 and GSC-005
murine glioblastoma models. Furthermore, even when we remove the immune component, Delta24-RGDOX can still increase the expression of IDO and AhR in cancer cells in vitro, indicating
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an IFNγ-independent mechanism of IDO induction by Delta-24-RGDOX; correspondingly, we
observed the activation and translocation of AhR from the cytoplasm to the nucleus in these virally
infected tumor cells. Importantly, IDO and AhR overexpression is implicated in brain
malignancies (23, 189). These data provided the rationale supporting the combination of Delta24-RGDOX and IDO inhibitors for the treatment of murine glioma.
Thus, to increase the anti-tumor immune effect of Delta-24-RGDOX, we tested the
addition of IDO inhibitors in two immunocompetent murine glioma models, GL261-5 and GSC005. We demonstrated the survival advantage or complete tumor eradication by the combination
treatment of IDO inhibitor and Delta-24-RGDOX over single-agent treatments in both models.
We reproduced these results in the highly aggressive B16 murine melanoma intracranial tumor
model. These data are consistent with our additional survival data in the GSC-005 model, where
we observed long term survival of IDO-KO mice compared to WT mice following intratumoral
administration of Delta-24-RGDOX; importantly, this result exhibits the on-target effect of IDO
inhibition and its enhanced therapeutic effect when combined with Delta-24-RGDOX. However,
we must note here that the survival curve of the combination of IDO inhibitor and Delta-24RGDOX we observed in the GL261-5 model was not similar to the survival curve of the GL2615 bearing IDO-KO mice treated with Delta-24-RGDOX. Here, there are a couple considerations
to make: first, the viral dose in the IDO-KO experiment was lower, and second, we used
Indoximod to test the therapeutic efficacy of its combination with Detla-24-RGDOX. Indoximod
is not considered a direct enzyme inhibitor; instead, it provides a Trp sufficiency signal to reverse
stress kinase signals that can inhibit mTORC signaling in surrounding T effector cells (27).
Further studies testing direct IDO inhibitors in the GL261-5 model will be required to determine
the therapeutic efficacy of direct IDO inhibitors in the context of direct IDO enzyme inhibitors.
Notably, we still see viral-induced cytopathic ability of Delta-24-RGDOX in cases of IDO
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inhibition, such as with the IDO inhibition in vitro by BGB-7204 or in the extreme case of IDO
inhibition in GSC-005 or GL261-5 bearing IDO-KO mice. Overall, these results indicate that
combined IDO inhibition and oncolytic adenoviral treatment presents no unwanted drug
interactions and highlight the potential therapeutic effects that can be seen in patients if treated
with this drug combination.
Our studies displayed that Delta-24-RGDOX transformed the murine glioblastoma from
a non-immunogenic to an immunogenic tumor, as indicated by an influx of CD3+ T cells and
other immune cells evident by our histopathological analysis and flow cytometry assays. This
conversion of immunogenicity by Delta-24-RGDOX increased the amounts of both activating and
immunosuppressive immune populations, which provided a target for the Indoximod or BGB7204 to work as intended. Furthermore, we showed that both Delta-24-RGD and Delta-24RGDOX could induce IDO expression and activation in the tumor cells, most likely through an
IFN-dependent mechanism, and thus increasing the likelihood of response to the IDO inhibitor.
Related to our study, Ladomersky et al. recently reported a durable survival benefit in the GL261
immunocompetent murine glioma model with the triple combination of CNS-penetrating IDO1
enzyme inhibitor, BGB-5777 (39) or BGB-7204 (57), anti-PD1 mAb, and radiotherapy; in that
study, the radiotherapy generated an immunogenic tumor, allowing the targets of the IDO enzyme
inhibitor and the anti-PD1 mAb to be exposed. These and our results are consistent with the
concept described by Sharma and Allison (41) that if a non-immunogenic tumor becomes
immunogenic, it should become more responsive to immunotherapy.
To our knowledge, our study is the first to report the efficacy of combining IDO inhibitors
and an armed oncolytic adenovirus in a murine glioblastoma model. In agreement with our study,
Berrong et al. recently reported an enhanced survival effect with addition of Trp-mimetic,
Indoximod, to the combination of an anti-OX40 agonist and a vaccine against HPV16 E7 in an
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HPV16-E6-E7/HRAS–driven lung epithelial cancer model (190). This result validates our
studies, which shows that IDO inhibition enhances the anti-cancer effects of OX40 activation.
This study also supports that this anti-cancer effect generated by the therapeutic strategy of
combined IDO inhibition and OX40 pathway activation is not limited to the treatment of glioma.
In contrast with the use of cancer vaccines, the use of oncolytic viruses does not require previous
knowledge about the tumor antigen load since the oncolytic virus can infect and lyse all RBdeficient cells to release tumor-associated antigens into the tumor microenvironment. Consistent
with the effects of their triple combination, we observed both a reduction in regulatory T cells and
an increase in CD8+ T cells in the tumors of mice treated with Delta-24-RGDOX and
Indoximod/BGB-7204. Furthermore, Berrong et al. showed an increase in tumor-antigen-specific
CD8+ T cells, which is consistent with our co-culture experiments in which we found increased
IFNγ and IL-2 responses against both viral and tumor antigens in splenocytes from brain tumor–
bearing mice treated with combined Delta-24-RGDOX and Indoximod/ BGB-7204. This result
also suggests the generation of a tumor-specific immune memory, as these splenocytes were
presented with the same cancer antigens after being extracted from the mouse in an ex vivo setting.
This finding, along with our discovery of 100% survival in re-challenged GL261-5-bearing mice
previously treated with combined Delta-24-RGDOX and Indoximod, strongly indicates the
presence of a tumor-specific immune memory generated by the combination treatment. These
results emphasize the importance of the host immune system for the development of therapeutic
efficacy and memory against tumor antigen. Similarly, the results from our CD4+ T cell depletion
survival experiment in the GL261-5 model revealed the requirement of the CD4+ T cell population
on the therapeutic efficacy of the combined Delta-24-RGDOX and IDO inhibitor treatment.
Our studies also demonstrate the antitumor immunosuppression generated via the IDOKyn circuitry in the context of oncolytic adenoviral infection. That is, the presence of Kyn was
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able to decrease the T-cell activation against both tumor and viral antigen that was generated by
the oncolytic virus. Consistently, T-cell activation generated by the oncolytic virus was reduced
in the presence of targets that constitutively overexpress IDO compared to IDO-WT targets. This
result led to the speculation that that the IDO-Kyn pathway aids in negative regulation of antitumor immunity during virotherapy, and it can be reversed with the use of IDO inhibitors.
The murine glioblastoma models utilized in this study do not express IDO. Thus, the
effects of the IDO inhibitor are presumably due to changes of the host immune tumor
microenvironment. The literature shows that IDO can be expressed by dendritic cells and
macrophages (147), but we did not identify the source of IDO in our model; doing so, through the
use of CyTOF or RNA sequencing of the brain tumors of differently treated mice, might elucidate
how our virus can alter IDO expression in different immune cell populations to produce more
immunosuppression within the tumor microenvironment. Still, our studies show that Delta-24RGDOX or IFNγ can increase the expression of IDO in vitro in different murine and human
glioma cells. Additionally, the infection of Delta-24-RGDOX in human cancer cells increased
AhR activity and its translocation into the nucleus, suggesting that activation of IDO, whose
catabolite, Kyn, is an agonist for AhR. AhR has been reported to cause immunosuppression in
glioblastoma via activation of Tregs (32, 33), induction of either apoptosis or dysfunction of
effector CD8+ T-cells, or activation of immunosuppressive macrophages and other population of
immune cells causing immunosuppression (46). This activation of IDO and AhR in the tumor
microenvironment cooperate to suppress tumor-specific immune responses, promoting glioma
immune evasion and tumor progression (32, 33). Importantly in our study, in addition to the
Delta-24-RGDOX induced AhR expression and activity in vitro, the in vivo brain tumors from
the virus-infected groups expressed and activated more IDO compared to control-treated mice,
indicating that the tumor microenvironment of this model contained an active IDO that could be
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involved in the subsequent activation of the Kyn-AhR cascade. Consistent with the negligible
levels of IDO or Kyn in PBS treated brain tumors, Treg and MDSC populations were nearly
undetectable in these samples of the GL261-5 model. Upon treatment with Delta-24-RGDOX, the
brain tumors displayed increases in the Treg and MDSC populations. This result was validated by
our RNA sequencing analyses that showed enrichment of the Treg and MDSC gene sets in Delta24-RGDOX murine brain tumors. When IDO inhibitors were combined with Delta-24-RGDOX,
the Treg and MDSC populations were diminished. These data are consistent with the new
paradigm of viro-immunotherapy, which supports the theory of oncolytic viruses transforming
immune-excluded tumors to more immunogenic one. Moreover, the subsequent decrease of the
Treg and MDSC populations when an IDO inhibitor is added to Delta-24-RGDOX underline the
ability of these inhibitors to decrease immunosuppressive populations.
In conclusion, we have shown for the first time that combined treatment with Delta-24RGDOX and IDO inhibitors produces long-term survival in a murine glioblastoma model without
any observable toxic effects. We further shown that this effect may be mediated by an increase in
cytotoxic T-cell activity, a decrease in immunosuppressive immune populations, and subsequent
generation of anti-glioma immune memory. This highly translatable study strongly suggests that
the use of IDO inhibitors with armed oncolytic adenoviruses will be a promising treatment for
patients with glioblastoma and other solid tumors.
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Chapter 13: Future Directions
The studies of this dissertation have shown that the modified oncolytic adenovirus armed
with OX40L, or Delta-24-RGDOX, can induce the expression and activation of the IDO pathway
upon infection of murine glioblastoma, a result that validated observations made from RNA
sequencing analyses. Further RNA sequencing analyses demonstrated that Delta-24-RGDOX
elicited expression of both Th2 and Th1 responses, which could explain the modest survival of
glioma bearing mice (191). We demonstrated that combined Delta-24-RGDOX and IDO inhibitor
treatment increases survival and aids in complete tumor regression of glioma bearing mice. This
antitumor effect was most likely due to enhanced anti-tumor and decreased immune suppressive
responses, most likely through a skewed Th1 response provided by the IDO inhibitor when added
to Delta-24-RGDOX (27, 39, 52, 190). This was evidenced by more infiltration of CD3+, CD4+,
and CD8+ T cells compared to the single treatment of Delta-24-RGDOX. Exploration of the
systemic splenocytes revealed that the combined Delta-24-RGDOX and IDO inhibitor treatment
led to enhanced T cell responses against tumor and viral antigens compared to Delta-24-RGDOX
alone, and that Kyn was able to reverse these T cell responses. Furthermore, the treatment of these
mice with Delta-24-RGDOX increased immune tolerant populations, Tregs and MDSCs, and
were decreased in the tumor microenvironment when an IDO inhibitor was added. This current
model is summarized in Figure 33.
Although these studies provide a significant rationale to combine IDO inhibitors with
armed oncolytic adenoviruses in the clinic, there is still much to be discovered regarding the basic
interactions of OX40, IDO, and AhR. There are few reports studying pathways of this tumor
necrosis superfamily and its direct effects on IDO and AhR signaling and vice versa (190, 192).
Studied separately, the consensus of IDO and AhR signaling in glioblastoma, is that it aids in a
tumor tolerant microenvironment (26, 189). Elucidation of the detailed biological underpinnings
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of OX40, IDO, and AhR signalling within the glioma microenvironment would yield valuable
insights into potential druggable targets that could be applied to the treatment of glioma.
Furthermore, our studies focused only on the use of IDO inhibitors. Very few AhR antagonists
are being studied pre-clinically and clinically (189, 193). We propose that additional studies using
AhR inhibitors will clarify which arm of the IDO-Kyn-AhR cascade causes more
immunosuppression within the tumor, which will provide a strong basis for the translation of IDO
or AhR inhibitors in combination with armed oncolytic adenoviruses into the clinic. We also
expect that new IDO and AhR inhibitors will arrive to the clinical arena soon and that their
addition to virotherapy might result in the improvement of the prognosis of patients with brain
tumors and other solid tumors.
Three clinical trials are determining the safety profile of combining Indoximod with
chemotherapy and/or radiation in adult and pediatric patients with recurrent glioma
(NCT02052648, NCT04049669, NCT02502708) are currently underway. Similarly, we propose
to translate the combination of Delta-24-RGDOX and Indoximod into a phase I clinical trial to
first determine the safety profile of the drug combination in patients with recurrent glioblastoma.
We predict that this combined therapy of Indoximod and Delta-24-RGDOX will improve the
survival of patients with recurrent glioblastoma.
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Figure 33: The immunological effects of Delta-24-RGDOX combined with IDO inhibitors
within the glioma microenvironment.
The microenvironment of gliomas is characterized by a paucity of T cells skewed towards the
Th2 phenotype. This Th2 phenotype promotes IL-4 function and recruitment of MDSCs,
Tregs, or anergic PD-1+ or CTLA-4+ T cells. Infection of gliomas with oncolytic viruses, such
as Delta-24-RGDOX, results in the induction of a Th1 phenotype with an increase of the
production of IL-12 or IFNγ. However, the viral infection activates both the IFNγ-driven IDOKyn-AhR cascade and the maintenance of immune suppression via activation of MDSCs and
Tregs. The addition of IDO inhibitors to virotherapy results in an imbalance of the signaling
with a predominance of Th1 and CD8+ cytotoxic T cells leading to the eradication of the tumor.
Figure created with BioRender.com.
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